<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80683</article-id><article-id pub-id-type="doi">10.7554/eLife.80683</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Mutant SF3B1 promotes malignancy in PDAC</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-282337"><name><surname>Simmler</surname><given-names>Patrik</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2883-275X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324268"><name><surname>Ioannidi</surname><given-names>Eleonora I</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282338"><name><surname>Mengis</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324269"><name><surname>Marquart</surname><given-names>Kim Fabiano</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324270"><name><surname>Asawa</surname><given-names>Simran</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282339"><name><surname>Van-Lehmann</surname><given-names>Kjong</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282340"><name><surname>Kahles</surname><given-names>Andre</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282341"><name><surname>Thomas</surname><given-names>Tinu</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324271"><name><surname>Schwerdel</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-67223"><name><surname>Aceto</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20839"><name><surname>Rätsch</surname><given-names>Gunnar</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107092"><name><surname>Stoffel</surname><given-names>Markus</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1304-5817</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-281610"><name><surname>Schwank</surname><given-names>Gerald</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0767-2953</contrib-id><email>schwank@pharma.uzh.ch</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a28rw58</institution-id><institution>Department of Biology, Institute of Molecular Health Sciences, ETH Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>Institute of Pharmacology and Toxicology, University of Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a28rw58</institution-id><institution>Department of Computer Science, Biomedical Informatics Group, ETH Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002n09z45</institution-id><institution>Swiss Institute of Bioinformatics</institution></institution-wrap><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a28rw58</institution-id><institution>Department of Biology, ETH Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01462r250</institution-id><institution>Biomedical Informatics Research, University Hospital Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>12</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e80683</elocation-id><history><date date-type="received" iso-8601-date="2022-05-31"><day>31</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-10-11"><day>11</day><month>10</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-06-19"><day>19</day><month>06</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.06.16.496393"/></event></pub-history><permissions><copyright-statement>© 2023, Simmler et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Simmler et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80683-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80683-figures-v3.pdf"/><abstract><p>The splicing factor SF3B1 is recurrently mutated in various tumors, including pancreatic ductal adenocarcinoma (PDAC). The impact of the hotspot mutation SF3B1<sup>K700E</sup> on the PDAC pathogenesis, however, remains elusive. Here, we demonstrate that Sf3b1<sup>K700E</sup> alone is insufficient to induce malignant transformation of the murine pancreas, but that it increases aggressiveness of PDAC if it co-occurs with mutated KRAS and p53. We further show that Sf3b1<sup>K700E</sup> already plays a role during early stages of pancreatic tumor progression and reduces the expression of TGF-β1-responsive epithelial–mesenchymal transition (EMT) genes. Moreover, we found that SF3B1<sup>K700E</sup> confers resistance to TGF-β1-induced cell death in pancreatic organoids and cell lines, partly mediated through aberrant splicing of <italic>Map3k7</italic>. Overall, our findings demonstrate that SF3B1<sup>K700E</sup> acts as an oncogenic driver in PDAC, and suggest that it promotes the progression of early stage tumors by impeding the cellular response to tumor suppressive effects of TGF-β.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PDAC mouse model</kwd><kwd>murine PDAC organoids</kwd><kwd>TGFb-signaling</kwd><kwd>apoptosis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Human Cancer Cells</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>185293</award-id><principal-award-recipient><name><surname>Schwank</surname><given-names>Gerald</given-names></name><name><surname>Simmler</surname><given-names>Patrik</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>176317</award-id><principal-award-recipient><name><surname>Stoffel</surname><given-names>Markus</given-names></name><name><surname>Simmler</surname><given-names>Patrik</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000781</institution-id><institution>European Research Council</institution></institution-wrap></funding-source><award-id>101001652</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012652</institution-id><institution>ETH Zürich Foundation</institution></institution-wrap></funding-source><award-id>PHRT-541</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001711</institution-id><institution>Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung</institution></institution-wrap></funding-source><award-id>212183</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Swiss Cancer League</institution></institution-wrap></funding-source><award-id>KLS-4834-08-2019</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012652</institution-id><institution>ETH Zürich Foundation</institution></institution-wrap></funding-source><award-id>LC-02-22</award-id><principal-award-recipient><name><surname>Asawa</surname><given-names>Simran</given-names></name><name><surname>Aceto</surname><given-names>Nicola</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100012652</institution-id><institution>ETH Zürich Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Thomas</surname><given-names>Tinu</given-names></name><name><surname>Kahles</surname><given-names>Andre</given-names></name><name><surname>Van-Lehmann</surname><given-names>Kjong</given-names></name><name><surname>Rätsch</surname><given-names>Gunnar</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>SF3B1-K700E, a gene mutaiton found recurrently mutated in pancreatic cancer, increases malignancy in an autochthonous mouse model of pancreatic cancer and induces resistance against TGF-β-induced apoptosis in vitro by missplicing of MAP3K7.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Genes involved in RNA splicing are frequently mutated in various cancer types (<xref ref-type="bibr" rid="bib50">Yoshida et al., 2011</xref>). The splicing factor subunit 3b 1 (SF3B1) is amongst the most commonly mutated components of the splicing machinery, with high incidence in myelodysplastic syndromes (MDS; <xref ref-type="bibr" rid="bib22">Je et al., 2013</xref>) and chronic lymphocytic leukemia (CLL; <xref ref-type="bibr" rid="bib37">Miao et al., 2019</xref>). However, also in various solid tumors, SF3B1 is recurrently mutated, including uveal melanoma (UVM; <xref ref-type="bibr" rid="bib16">Furney et al., 2013</xref>), breast cancer (BRCA; <xref ref-type="bibr" rid="bib15">Fu et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Maguire et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Sun et al., 2020</xref>), prolactinomas (<xref ref-type="bibr" rid="bib28">Li et al., 2020</xref>), hepatocellular carcinoma (HCC; <xref ref-type="bibr" rid="bib53">Zhao et al., 2021</xref>), and pancreatic adenocarcinoma (PDAC; <xref ref-type="bibr" rid="bib2">Bailey et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Yang et al., 2021</xref>). As part of the U2 small nuclear ribonucleoprotein (U2 snRNP) SF3B1 exerts an essential function in RNA splicing by recognizing the branchpoint sequence (BPS) of nascent RNA transcripts (<xref ref-type="bibr" rid="bib46">Wahl et al., 2009</xref>; <xref ref-type="bibr" rid="bib52">Zhang et al., 2020</xref>). This process is crucial for the definition of the 3’ splice site (3’ ss) of the upstream exon-intron boundary, a prerequisite for the accurate removal of introns (<xref ref-type="bibr" rid="bib46">Wahl et al., 2009</xref>). It is well understood that hotspot mutations in SF3B1 at HEAT repeats 5–9 allow the recognition of an alternative BPS, resulting in the inclusion of a short intronic region into the mature messenger RNA (mRNA; <xref ref-type="bibr" rid="bib1">Alsafadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Canbezdi et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Darman et al., 2015</xref>; <xref ref-type="bibr" rid="bib13">DeBoever et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Kesarwani et al., 2017</xref>). These alternatively spliced transcripts are prone to degradation through nonsense-mediated RNA decay (NMD) (<xref ref-type="bibr" rid="bib11">Darman et al., 2015</xref>). Several recent studies have evaluated the mechanistic contribution of genes misspliced by oncogenic SF3B1 to tumor progression. So far, missplicing of <italic>PPP2R5A</italic> was found to increase malignancy through stabilizing c-Myc (<xref ref-type="bibr" rid="bib31">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib48">Yang et al., 2021</xref>), and aberrant <italic>MAP3K7</italic> splicing was reported to promote NF-κB-driven tumorigenesis (<xref ref-type="bibr" rid="bib33">Liu et al., 2021</xref>).</p><p>Despite compelling evidence on the oncogenic role of mutated SF3B1 in hematologic malignancies, its contribution to the formation or progression of solid tumors is less understood. Since splicing deregulation has been reported as a hallmark of PDAC, with SF3B1 being recurrently mutated (<xref ref-type="bibr" rid="bib2">Bailey et al., 2016</xref>), we aimed at elucidating the impact of the frequently occurring SF3B1<sup>K700E</sup> mutation to the pathogenesis of this tumor type. We demonstrate that <italic>Sf3b1<sup>K700E</sup></italic> increases malignancy in a mouse model for PDAC and decreases the sensitivity to TGF-β-responsive EMT genes. Experiments in pancreatic organoids and cell lines further provide evidence that SF3B1<sup>K700E</sup> protects from TGF-β-induced cell death and that TGF-β-resistance is partly mediated through missplicing of <italic>Map3k7</italic>. Together, our work suggests that SF3B1<sup>K700E</sup> exerts its oncogenic role in PDAC by dampening the tumor-suppressive effect of TGF-β.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SF3B1<sup>K700E</sup> is a tumor driver during early stages of PDAC formation</title><p>RNA processing has been previously identified as a hallmark of pancreatic cancer in the published Pancreatic Cancer Australian (PACA-AU) cohort (<xref ref-type="bibr" rid="bib2">Bailey et al., 2016</xref>). Validating these findings, we found that genes encoding for the splice factors RBM10, SF3B1, and U2AF1 are also frequently mutated in the Pancreatic Cancer Canadian (PACA-CA) cohort (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). In accordance with its described function as a tumor suppressor (<xref ref-type="bibr" rid="bib17">Hernández et al., 2016</xref>), 56% of the mutations found in RBM10 lead to a truncated protein. Conversely, in SF3B1 and U2AF1 the majority of mutations were missense mutations that occurred at hotspot sites, indicating a neomorphic function of the mutated proteins. Like in other cancer types, also in PDAC the most frequently found mutation in SF3B1 led to a lysine (K) to glutamic acid (E) change at position 700 (SF3B1<sup>K700E</sup>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Therefore, we experimentally tested if the SF3B1<sup>K700E</sup> mutation contributes to PDAC malignancy by generating a mouse model where the <italic>Sf3b1<sup>K700E</sup></italic> mutation is specifically activated in the pancreas using Ptf1a-Cre (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). First, we tested if <italic>Sf3b1<sup>K700E/+</sup></italic> alone is sufficient to induce PDAC formation. However, heterozygous activation of the <italic>Sf3b1<sup>K700E</sup></italic> allele did not have any effect on survival of mice or weight of the pancreas after 300 days (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Furthermore, assessing the pancreata histologically for two prognostic markers for PDAC, Cytokeratine-19 (CK19) and Mucin 5AC (MUC5AC), revealed no difference to wild type control mice (CK19 was restricted to pancreatic ducts and MUC5AC was not expressed; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D, E</xref>). Next, we assessed if the K700E mutation increases aggressiveness of PDAC, and crossed the <italic>Sf3b1<sup>K700E</sup></italic> allele into the <italic>Ptf1a-Cre; Kras<sup>G12D/+</sup>; Trp53<sup>fl/fl</sup></italic> (KPC) mouse model, which is known to induce PDAC within 2–3 months (<xref ref-type="bibr" rid="bib3">Bardeesy et al., 2006a</xref>; <xref ref-type="bibr" rid="bib19">Hingorani et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Marino et al., 2000</xref>). Importantly, KPC-<italic>Sf3b1<sup>K700E/+</sup></italic> animals displayed a significantly shorter survival (mean survival 57 days vs. 64 days), and an increased tumor size compared to KPC mice at the age of 9 weeks (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>). However, since at this timepoint similar amounts of tissue fibrosis and CK19 positive cells were observed in <italic>Sf3b1<sup>K700E/+</sup></italic> mutant vs. <italic>Sf3b1<sup>+/+</sup></italic> KPC tumors (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–I</xref>), we next assessed if SF3B1<sup>K700E</sup> already promotes malignancy at early stages of tumorigenesis. Indeed, when we analyzed pancreata of 5-week-old mice, already 67% of KPC-<italic>Sf3b1<sup>K700E/+</sup></italic> mice vs. 25% of KPC mice developed PDAC. Moreover, we observed an increase in acinar-to-ductal metaplasia (ADM) formation and in the number of CK19 and MUC5AC positive cells, and a reduction in ß-amylase staining (<xref ref-type="fig" rid="fig1">Figure 1G–J</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1J, K</xref>). Further supporting that SF3B1<sup>K700E</sup> already plays a role in early stages of carcinogenesis, <italic>Sf3b1<sup>K700E/+</sup></italic> also had an effect on tumor malignancy when introduced into <italic>Kras<sup>G12D/+</sup></italic> (KC) mice, which is a model for pre-cancerous pancreatic neoplasms with sporadic PDAC formation after a prolonged latency period (<xref ref-type="bibr" rid="bib19">Hingorani et al., 2005</xref>). At 43 weeks of age, the area of neoplastic pancreas tissue was increased, and in 64% of KC-<italic>Sf3b1<sup>K700E/+</sup></italic> mice vs. 10% of KC mice the lesions had already progressed to PDAC (<xref ref-type="fig" rid="fig1">Figure 1L</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1L</xref>). In addition, the time of disease-free survival was significantly shortened in KC-<italic>Sf3b1<sup>K700E/+</sup></italic> mice vs. KC mice (<xref ref-type="fig" rid="fig1">Figure 1K</xref>). Finally, in a model for advanced cancer, where KPC and KPC<italic>-Sf3b1<sup>K700E</sup></italic> cells were harvested from fully developed PDAC tumors and expanded in vitro before being orthotopically transplanted, we did not observe differences in tumor growth (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1M, N</xref>). Together, our data demonstrate that the SF3B1<sup>K700E</sup> contributes to PDAC malignancy by accelerating the formation of precursor lesions.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Sf3b1<sup>K700E</sup> increases aggressiveness of murine PDAC.</title><p>(<bold>A</bold>) Schematic overview of the <italic>Sf3b1<sup>K700E/+</sup></italic> knockin model. Arrows indicate direction of the translatable code of the gene. An A to G conversion at base position 2098, induced by Cre-recombination, results in a lysine to glutamic acid mutation at amino acid position 700 of the protein. (<bold>B</bold>) Survival of WT and <italic>Sf3b1<sup>K700E/+</sup></italic> mice followed over 300 days (n=8). (<bold>C</bold>) Pancreas weight of WT and <italic>Sf3b1<sup>K700E/+</sup></italic> mice at 300 days of age (3 males and 3 females for each genotype). Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>D</bold>) Representative photographs of WT, KPC, and KPC-Sf3b1<sup>K700E/+</sup> pancreata of mice 9 weeks old mice. (<bold>E</bold>) Survival of KPC and KPC-Sf3b1<sup>K700E/+</sup> mice, p-value was determined by Log-rank (Mantel-Cox) testing. (<bold>F</bold>) Pancreatic weight of KPC and KPC-Sf3b1<sup>K700E/+</sup> mice at 9 weeks of age. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>G</bold>) Representative micrograph images of H&amp;E, MUC5AC, β-amylase and CK19 staining of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 5-week-old mice. Scale bar is 50 μM (H&amp;E) or 100 μM (IF). (<bold>H</bold>) Quantification of β-amylase (<bold>H</bold>), MUC5AC (<bold>I</bold>) and CK19 (<bold>J</bold>) staining shown in (<bold>G</bold>). Per specimen, the average value of 5 random microscopy fields is displayed, a two-tailed unpaired t-test was used to compute the indicated p-value. Error bar represents standard error of the mean (SEM). (<bold>K</bold>) Survival of <italic>Kras<sup>G12D/+</sup></italic> and <italic>Kras<sup>G12D/+</sup>; Sf3b1<sup>K700E/+</sup></italic> mice. p-Value was determined by Log-rank (Mantel-Cox) testing. (<bold>L</bold>) Percentage of mice at 43 weeks of the indicated genotypes showing PanINs (blue) or PanINs and PDAC formation (red). p-Value indicates significance of the difference in PDAC formation, computed by Chi-square test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Sf3b1<sup>K700E</sup> increases aggressiveness of murine PDAC.</title><p>(<bold>A</bold>) Incidence of mutations in splicing factors in PDAC patients derived from the ICGC database (PACA-AU, n=391 and PACA-CA, n=268). (<bold>B</bold>) Incidence of <italic>SF3B1</italic> missense mutations in PDAC patients derived from PACA-AU and PACA-CA. (<bold>C</bold>) Representative Sanger-sequencing results of the <italic>Sf3b1<sup>K700E/+</sup></italic> mutation (T&gt;C) of cDNA isolated from pancreata at 43 weeks of age of <italic>Ptf1a-Cre</italic> (WT) or <italic>Ptf1a-Cre; Sf3b1<sup>K700E/+</sup></italic> (<italic>Sf3b1<sup>K700E/+</sup></italic>) mice. (<bold>D</bold>) Representative micrograph images of CK19 staining of WT and Sf3b1<sup>K700E/+</sup> pancreata of 43-week-old mice. Scale bar is 100 μM. (<bold>E</bold>) Quantification of β-amylase staining. Per specimen, the average value of 5 random microscopy fields is displayed, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>F</bold>) Representative micrograph images of CK19 staining of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 9-week-old mice. Scale bar is 100 μM. (<bold>G</bold>) Quantification of CK19 staining of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 9-week-old mice. Per specimen, the average value of 5 random microscopy fields is displayed, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>H</bold>) Representative micrograph images of Masson Goldner staining of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 9-week-old mice. Scale bar is 100 μM. (<bold>I</bold>) Quantification of collagen positive area (Masson Goldner staining) of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 9-week-old mice. Per specimen, the average value of 5 random microscopy fields is displayed, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>J</bold>) Representative micrograph images of H&amp;E staining of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 5-week-old mice. Scale bar is 50 μM. (<bold>K</bold>) Quantification of ADM structures of KPC and KPC-Sf3b1<sup>K700E/+</sup> pancreata of 5-week-old mice. Per specimen, the average value of 5 microscopy fields of areas without or with minimal PanIN formation is displayed, a two-tailed unpaired t-test was used to compute the indicated p-value. Error bar represents SEM. (<bold>L</bold>) Affected area (including PanINs and PDAC) of WT, <italic>Kras<sup>G12D/+</sup></italic> and <italic>Kras<sup>G12D/+</sup>; Sf3b1<sup>K700E/+</sup></italic> pancreata at 43 weeks of age. Mann-Whitney test was used to compute the indicated p-value. (<bold>M–N</bold>) Photographs (<bold>M</bold>) and weight (<bold>N</bold>) of pancreata 2 weeks after orthotopic transplantation of KPC and KPC-Sf3b1<sup>K700E/+</sup> cells. Scale bar is 1 cm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig1-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-2"><title>SF3B1<sup>K700E</sup> reduces expression of EMT genes in pancreatic tumors</title><p>In order to elucidate the functional impact of SF3B1<sup>K700E</sup> on the transcriptome, we isolated cancer cells of mouse tumors by fluorescence-activated cell sorting (FACS) of Epithelial cell adhesion molecule (EpCAM) positive cells and performed RNA-sequencing (RNA-seq) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). High purity of isolated tumor cells was confirmed by the absence of sequencing reads for <italic>Trp53</italic> exons 2–10, which are excised via Cre-recombination specifically in tumor cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), and by the presence of the <italic>Sf3b1<sup>K700E</sup></italic> mutation in 38% of the transcripts (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Principal component analysis separated the sequenced replicates (3 KPC and 4 KPC-Sf3b1<sup>K700E/+</sup> tumors) according to the genotype, indicating a major impact of the K700E mutation on the transcriptome (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><p>We next performed gene set enrichment analysis (GSEA), which revealed IFN-α-response as the most significantly enriched pathway in KPC-Sf3b1<sup>K700E/+</sup> tumor cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). This result is in line with a previous study, which found that aberrant splicing caused by SF3B1 inhibition or oncogenic SF3B1 mutations induces an IFN-α-response through retinoic acid-inducible gene I (RIG-I) mediated recognition of cytosolic aberrant RNA-species (<xref ref-type="bibr" rid="bib9">Chang et al., 2021</xref>). Interestingly, epithelial-mesenchymal transition (EMT) emerged as the most significantly attenuated gene set in KPC-Sf3b1<sup>K700E/+</sup> cells (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). We first confirmed downregulation of the most significantly depleted gene of the EMT gene set, the glycoprotein Tenascin-C (<italic>Tnc</italic>), by qPCR on additional KPC-Sf3b1<sup>K700E/+</sup> tumor samples (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and by histology in KPC-Sf3b1<sup>K700E/+</sup> PDAC sections (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Next, we assessed if the reduction of EMT genes was induced cell-autonomously by the <italic>Sf3b1<sup>K700E/+</sup></italic> mutation, or if it was an indirect consequence of the altered micro-environment in <italic>Sf3b1<sup>K700E</sup></italic> KPC tumors. We therefore compared the expression of the 15 most significantly depleted EMT genes (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) in vitro in <italic>Sf3b1<sup>K700E</sup></italic> vs. <italic>Sf3b1 WT</italic> KPC pancreatic organoids. Importantly, 71% of the analysed genes were significantly reduced in KPC-Sf3b1<sup>K700E/+</sup> vs. KPC organoids, with none of the genes showing a trend towards elevated expression (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). To rule out that differences in EMT gene expression could be a consequence of differences in the tumor stage between <italic>Sf3b1<sup>K700E</sup></italic> versus <italic>Sf3b1</italic> WT KPC tumors, we next established non-cancerous pancreatic organoids from LSL-<italic>Kras<sup>G12D/+</sup>; Trp53<sup>fl/fl</sup>; Sf3b1<sup>flK700E/+</sup></italic> or <italic>Sf3b1</italic><sup>+/<italic>+</italic></sup> and LSL-<italic>Kras<sup>G12D/+</sup>; Trp53<sup>fl/fl</sup></italic> mice and induced recombination in vitro through lentiviral Cre transduction. Importantly, also in this experimental setup 55% of the analysed EMT genes were significantly downregulated in <italic>Sf3b1<sup>K700E</sup></italic> vs. <italic>Sf3b1</italic> WT organoids, with only one of the analysed genes showing a minor trend for elevated expression (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Together, these data indicate that <italic>Sf3b1<sup>K700E</sup></italic> mediates downregulation of EMT-related genes in PDAC a cell autonomous manner.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Sf3b1<sup>K700E</sup></italic> induces downregulation of EMT.</title><p>(<bold>A</bold>) Gene-set enrichment analysis (GSEA) enrichment plot of epithelial-mesenchymal transition (EMT), representing the most deregulated pathway of the GSEA-Hallmark pathways when comparing KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=4) sorted tumor cells. (<bold>B</bold>) Top 15 of downregulated genes of the GSEA-EMT gene list in sorted KPC-Sf3b1<sup>K700E/+</sup> cells (FDR &lt; 0.05, logCPM &gt;1). (<bold>C</bold>) <italic>Tnc</italic> expression in KPC (n=7) and KPC-Sf3b1<sup>K700E/+</sup> (n=7) tumors, assessed by RT-qPCR. Error bar represent SEM. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>D</bold>) Representative Immunofluorescence staining of CK19 (red) and TNC (green) in murine PDAC samples, counterstained with DAPI (blue). Scale bar is 50 μm. (<bold>E</bold>) Quantification of TNC staining in KPC (n=6) and KPC-Sf3b1<sup>K700E/+</sup> (n=6) tumors. The averaged area of TNC staining in three randomly chosen fields per tumor specimen was compared by a two-tailed unpaired t-test. (<bold>F</bold>) The expression of the EMT genes displayed in (<bold>B</bold>) was assessed by RT-qPCR in tumor cells (KPC, n=11 and KPC-Sf3b1<sup>K700E/+</sup> n=11) after one passage of ex-vivo culture. For analysis, Ct-values of the indicated genes were normalized to <italic>Actb</italic> and a two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>G</bold>) Representative micrographs of KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=3) cancer organoid lines treated with TGF-β1 (10 ng/ml) for 48 hr. Matrigel was detached prior to staining with crystal violet, allowing quantification of cells migrated through the matrigel matrix and attached at the cell culture plate. Scale bar is 1 mm (panel above) or 100 μm (panel below). (<bold>H</bold>) Quantification of micrographs shown in (<bold>G</bold>). The fraction of attached organoids was calculated by dividing the number of attached organoids by the number of total organoids contained in the matrigel dome. The experiment was performed independently three times for every cell line, the average of all replicates is shown. Error bar represents SEM. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>I</bold>) Representative micrographs of wound healing assay of PANC-1 WT and PANC-1 SF3B1<sup>K700E/+</sup> cells pre-treated with TGF-β1 (10 ng/ml) for 24 hours at the indicated time points after performing the scratch. Scale bar is 100 μm. (<bold>J</bold>) Quantification of wound healing assay of PANC-1 WT and PANC-1 SF3B1<sup>K700E/+</sup> cells, displaying the ratio of wound-closure of cells treated with TGF-β1 or without (Ctrl). The experiment was independently performed three times. Error bar represents standard deviation (SD). A two-tailed unpaired t-test was used to compute the indicated p-values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title><italic>Sf3b1<sup>K700E</sup></italic> induces downregulation of EMT.</title><p>(<bold>A</bold>) Integrated genome viewer (IGV) displaying RNA-seq reads of <italic>Trp53</italic> of sorted KPC and KPC-Sf3b1<sup>K700E/+</sup> cells. (<bold>B</bold>) Principal component analysis showing the variance in two dimensions in relation to the genotypes of the sorted tumor cells (Wildtype = KPC, K700E=KPC-Sf3b1<sup>K700E/+</sup>). (<bold>C</bold>) Results of GSEA analysis, displaying most enriched (top) and depleted (bottom) GSEA-Hallmark pathways in KPC-Sf3b1<sup>K700E/+</sup> animals. (<bold>D</bold>) RT-qPCR analysis of EMT genes of KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=3) in vitro activated cancer cell lines. The experiment was performed independently four times for every cell line, the average of all replicates is shown. Error bar represent SEM. <italic>Col3a1, Sfrp1, Igfbp4, Col1a2, Mmp2,</italic> and <italic>Lama1</italic> were not detected and therefore excluded from analysis (see methods for details). Two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>E, F</bold>) RT-qPCR analysis of EMT genes displayed in <xref ref-type="fig" rid="fig2">Figure 2B</xref> in three different KPC cell lines treated with TGF-β1 (10 ng/ml) (<bold>E</bold>) or TNF-α (100 ng/ml) (<bold>F</bold>) for 24 hr. The experiment was performed independently three times for every cell line. Error bar represent SEM. <italic>Col3a1, Sfrp1, Igfbp4, Col1a2, Mmp2,</italic> and <italic>Lama1</italic> were not detected and therefore excluded from analysis (see methods for details). (<bold>G</bold>) RT-qPCR analysis of EMT genes of KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=3) in vitro activated cancer cell lines treated with TGF-β1 (10 ng/ml) for 24 hr. The experiment was performed independently four times for every cell line, the average of all replicates and SEM is shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig2-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-3"><title>SF3B1<sup>K700E</sup> confers resistance to TGF-β1-induced apoptosis in organoids and cell lines</title><p>The two major EMT-promoting cytokines are TNF-α and TGF-β (<xref ref-type="bibr" rid="bib7">Bulle and Lim, 2020</xref>). We therefore determined if the EMT genes that are most significantly downregulated by <italic>Sf3b1<sup>K700E</sup></italic> in KPC tumours are induced by TNF-α or TGF-β. Importantly, we found that 80% of the analysed genes were strongly induced by TGF-β in tumour derived KPC cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>), whereas TNF-α significantly upregulated only 20% of these genes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). Furthermore, we observed that in vitro induced <italic>Sf3b1<sup>K700E</sup></italic> KPC cells fail or only partially induce 6 of the 9 assessed EMT genes when stimulated with TGF-β (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>). In line with these results, in vitro induced <italic>Sf3b1<sup>K700E</sup></italic> KPC organoids exhibit a sixfold decrease in matrigel invasion compared to KPC control organoids when stimulated with TGF-β (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>). Moreover, human PANC-1 cells expressing SF3B1<sup>K700E</sup> display a reduced migratory rate compared to control PANC-1 cells expressing wildtype SF3B1 in a wound healing assay upon TGF-β stimulation (<xref ref-type="fig" rid="fig2">Figure 2I and J</xref>).</p><p>In pancreatic lesions TGF-β induces EMT, followed by apoptosis of the affected cells in a process termed lethal EMT (<xref ref-type="bibr" rid="bib12">David et al., 2016</xref>). This prompted us to speculate that SF3B1<sup>K700E</sup> could drive PDAC progression by reducing sensitivity of epithelial cells to TGF-β-mediated apoptosis. Performing immunofluorescence staining for cleaved caspase 3 in KPC tumors, we first confirmed that the majority of apoptotic cells reside in the lumen of PanINs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>), and that these cells are negative for the epithelial marker E-cadherin and positive for the mesenchymal marker Fibronectin-1 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib20">Hruban et al., 2006</xref>). We then analysed <italic>Sf3b1<sup>K700E</sup></italic> tumors by immunofluorescence staining. In line with our hypothesis, we observed a reduction in luminally extruded cells and a reduction in cleaved caspase 3-positive cells (CC3, <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). To further analyse the impact of <italic>Sf3b1<sup>K700E</sup></italic> on the tumor suppressive effect of TGF-β, we exposed <italic>Sf3b1</italic> WT and <italic>Sf3b1<sup>K700E</sup></italic> KPC tumor organoids to TGF-β1. We again observed reduced cleaved caspase 3 and 7 activity in <italic>Sf3b1</italic> mutant organoids, and a greatly increased survival rate (72% vs 17% surviving organoids, <xref ref-type="fig" rid="fig3">Figure 3C–E</xref>). Since results from our mouse models indicate that the <italic>Sf3b1<sup>K700E</sup></italic> mutation already plays a role during early stages of carcinogenesis (<xref ref-type="fig" rid="fig1">Figure 1G–L</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>), and the tumor-suppressing effect of TGF-β is most prominent on pre-cancerous epithelial cells (<xref ref-type="bibr" rid="bib36">Massagué, 2008</xref>), we additionally established organoid lines with- and without <italic>Sf3b1<sup>K700E</sup></italic> from non-cancerous mouse pancreata. While <italic>Sf3b1<sup>K700E</sup></italic> led to slightly reduced proliferation without supplementation of TGF-β1 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>), treatment with TGF-β1 led to significantly lower caspase 3 and 7 activity in <italic>Sf3b1<sup>K700E/+</sup></italic> vs. wildtype organoids and to significantly enhanced survival (77% vs 3%) (<xref ref-type="fig" rid="fig3">Figure 3F–H</xref>). Likewise, also in <italic>Kras<sup>G12D/+</sup></italic> organoids, SF3B1<sup>K700E</sup> led to increased survival in the presence of TGF-β1 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). Finally, exposure to low levels (1 ng/ml and 2 ng/ml) of TGF-β1 also allowed long-term expansion of <italic>Sf3b1<sup>K700E/+</sup></italic> organoids (analysed for over 120 days), while the number of <italic>Sf3b1</italic> WT organoids rapidly declined within the first 15 days (<xref ref-type="fig" rid="fig3">Figure 3I</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G, H</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Sf3b1<sup>K700E</sup></italic> reduces TGF-β-induced apoptosis.</title><p>(<bold>A</bold>) Representative microscopy images of E-Cadherin (green) and CC3 (red) in murine PDAC samples. Scale bar is 50 μm. (<bold>B</bold>) Quantification of CC3 positive cells in KPC (n=8) and KPC-Sf3b1<sup>K700E/+</sup> (n=7) tumor samples. The average number of CC3 positive cells of 5 microscopic fields is plotted, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>C</bold>) Immunofluorescence staining of E-Cadherin (green) and Cleaved Caspase 3 (CC3, red) in WT and Sf3b1<sup>K700E/+</sup> organoids exposed to TGF-β1 (10 ng/ml) for 12 hr. CC3-positive cells are highlighted by white dashed lines. Scale bar is 100 μm. (<bold>D</bold>) Quantification of Cleaved Caspase 3 and 7 (CC3/7) activity measured by Caspase-Glo assay of KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=4) in vitro activated cancer cell lines treated with TGF-β1 (10 ng/ml) for 24 hr. The experiment was repeated independently twice for every cell line, the average of the replicates is shown, error bar represents SEM. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>E</bold>) Quantification of viable organoids of the indicated genotype exposed to 10 ng/ml TGF-β1 for 48 hr, normalized to organoid numbers of untreated control samples. Each data point shows a different organoid line. For each organoid line, the experiment was independently performed three times, the average of replicates and SEM is plotted. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>F</bold>) Representative microscopy images of WT and <italic>Sf3b1<sup>K700E/+</sup></italic> organoids exposed to 10 ng/ml TGF-β1 for 48 hr. Scale bar is 500 μM. (<bold>G</bold>) Quantification of CC3/7 in WT and <italic>Sf3b1<sup>K700E/+</sup></italic> organoids exposed to 10 ng/ml TGF-β1 for 48 hr. The experiment was repeated independently four times, error bar represents SEM. Two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>H</bold>) Quantification of viable organoids of the indicated genotype exposed to 10 ng/ml TGF-β1 for 48 hr, normalized to organoid numbers of untreated control samples. Each data point shows a different organoid line. For each organoid line, the experiment was independently performed three times, the average of replicates and SEM is plotted. Two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>I</bold>) Organoid count of organoids cultured in medium containing 1 ng/ml TGF-β1 for up to 120 days. One organoid line per genotype was used, the experiment was repeated three times independently. (<bold>J</bold>) Viability of the human pancreatic duct cell line H6c7 overexpressing wildtype or mutated SF3B1 after 72 hr of exposure to 10 ng/ml TGF-β1 assessed by crystal violet staining. The optical density of TGF-β1-treated cells was normalized to untreated control cells. The experiment was independently performed three times, error bar represents SD. A two-tailed unpaired t-test was used to compute the indicated p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>Sf3b1<sup>K700E</sup></italic> reduces TGF-β-induced apoptosis.</title><p>(<bold>A</bold>) Representative microscopy images of CC3 (red) in KPC tumor samples. Scale bar is 50 μm. (<bold>B</bold>) Quantification of CC3 positive cells according to location (inside of PanIN lumen or outside of lumen) in 6 KPC tumor samples. (<bold>C</bold>) Representative microscopy images of FN1 (green) in murine PDAC. Scale bar is 50 μm. (<bold>D</bold>) Blinded quantification of luminal necrosis in KPC (n=5) and KPC-Sf3b1<sup>K700E/+</sup> (n=6) tumor samples. The average number of necrotic cells per PanIN lesion is plotted, two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>E</bold>) Proliferation of pancreatic ductal organoids derived from WT and <italic>Sf3b1<sup>K700E/+</sup></italic> mice without TGF-β1 supplementation. Error bar represent SEM. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>F</bold>) Organoid count of organoids of the indicated genotypes exposed to 10 ng/ml TGF-β1 for 48 hr. Error bar represent SEM. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>G</bold>) Organoid count of organoids cultured in medium containing 2 ng/ml TGF-β1 for the indicated period of time. One organoid line for each genotype was used, the experiment was independently performed twice. Error bar represent SEM. (<bold>H</bold>) Representative microscopy images of WT and <italic>Sf3b1<sup>K700E/+</sup></italic> organoids exposed to 1, 2, or 5 ng/ml TGF-β1 at the indicated number of passages. Scale bar is 500 μM. (<bold>I</bold>) Viability of indicated cell lines overexpressing wildtype or mutated SF3B1 after 72 hr of exposure to 10 ng/ml TGF-β1. The experiment was independently performed twice, error bar shows SD. A two-tailed unpaired t-test was used to compute indicated p-values (<bold>J</bold>) Normalized growth of the pancreatic duct cell line H6c7 overexpressing SF3B1-WT or SF3B1-K700E after 4 days of culture in normal growth medium. The experiment was independently performed twice, error bar shows SD. A two-tailed unpaired t-test was used to compute indicated p-value.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig3-figsupp1-v3.tif"/></fig></fig-group><p>To assess if reduced sensitivity to TGF-β is also observed in human pancreas cells containing the SF3B1<sup>K700E</sup> mutation, we stably overexpressed either wildtype or mutated SF3B1 in the human pancreatic duct cell line H6c7. This cell line is derived from healthy pancreatic tissue, which unlike all tested human PDAC-derived cell lines (BxPC-3, Mia PaCa-2, PANC-1, and PSN-1) is still partially responsive to the growth-suppressive effect of TGF-β signalling (<xref ref-type="fig" rid="fig3">Figure 3J</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I</xref>). In line with our results from murine PDAC, overexpression of mutant SF3B1<sup>K700E</sup> resulted in an increased viability upon TGF-β1 exposure compared to overexpression of wildtype SF3B1 (<xref ref-type="fig" rid="fig3">Figure 3J</xref>), while no effect of SF3B1<sup>K700E</sup> on proliferation was observed in absence of TGF-β1 treatment in human pancreatic duct cells and PDAC cell lines (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>).</p></sec><sec id="s2-4"><title>SF3B1<sup>K700E</sup> reduces TGF-β sensitivity through <italic>Map3k7</italic> missplicing in organoids and cell lines</title><p>To identify how SF3B1<sup>K700E</sup> could mediate the observed TGF-β resistance in pancreatic cells, we next assessed the impact of the mutation on RNA-splicing. By analysing RNA-seq data from sorted KPC vs. KPC-Sf3b1<sup>K700E/+</sup> tumor cells we predominantly identified alternative 3’ splice events (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), with cryptic 3’ ss showing an upstream adenosine enrichment and a less pronounced polypyrimidine tract most frequently located 8–14 bases upstream of the canonical 3’ ss (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). These findings are in accordance with previous splice-analyses performed in various murine SF3B1 mutant tissues (<xref ref-type="bibr" rid="bib33">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Mupo et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Obeng et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Yin et al., 2019</xref>). Next, we sought to determine which of the identified SF3B1<sup>K700E</sup>-dependent alternative splice events are conserved between mice and humans. Due to limited publicly available RNA-seq datasets in human PDAC, we analysed a pan-cancer dataset containing samples of 32 different cancer types. In agreement with previous studies, we found that also in human cancers the SF3B1<sup>K700E</sup> hotspot mutation leads to a predominant use of cryptic 3’ ss (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A, B</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>; <xref ref-type="bibr" rid="bib1">Alsafadi et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">DeBoever et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Kesarwani et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Wang et al., 2016</xref>). Importantly, we further identified 11 genes that contained an alternative 3’ splice-event linked to SF3B1<sup>K700E</sup> in human tumors as well as in KPC mice (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Of those genes, <italic>MAP3K7</italic> (formerly known as TGF-β activated kinase 1/<italic>TAK1</italic>) in particular raised our attention. It is a well-described effector of cytokine-signalling that mediates non-canonical TGF-β signalling (<xref ref-type="bibr" rid="bib27">Kim and Choi, 2012</xref>), and it was recently shown to induce EMT and apoptosis in TGF-β-stimulated human mammary cells (<xref ref-type="bibr" rid="bib45">Tripathi et al., 2019</xref>). Using targeted RNA-seq, we discovered that one third of <italic>Map3k7</italic> transcripts were misspliced in pancreata of <italic>Sf3b1<sup>K700E/+</sup></italic> and KPC-Sf3b1<sup>K700E/+</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Confirming inter-species conservation of this alternative splice-event, <italic>MAP3K7</italic> was also misspliced in H6c7 cells and human PDAC cell lines overexpressing SF3B1<sup>K700E</sup> (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Notably, when we further assessed SF3B1<sup>K700E</sup> dependent alternative splicing of <italic>Ppp2r5a</italic>, which was reported to impair apoptosis via post-translational modification of BCL2 in leukaemia (<xref ref-type="bibr" rid="bib31">Liu et al., 2020a</xref>), we did not observe significant alternative 3’ss usage or mRNA expression of <italic>Ppp2r5a</italic> in KPC-<italic>Sf3b1<sup>K700E</sup></italic> tumor cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E, F</xref>). This observation indicates tissue-specificity of <italic>Ppp2r5a</italic> missplicing.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>SF3B1-K700E induces aberrant splicing of MAP3K7 in human and mouse PDAC.</title><p>(<bold>A</bold>) Summary of alternative splice events detected in KPC-Sf3b1<sup>K700E/+</sup> sorted tumor cells (PSI &gt; 0.1, p&lt;0.01). (<bold>B</bold>) Histogram displaying the distance of cryptic 3’splice-site (ss) from the adjacent canonical 3’ss in sorted KPC-Sf3b1<sup>K700E/+</sup> tumor cells on a logarithmic scale. (<bold>C</bold>) Consensus 3’ ss motif in proximity of the canonical (top) and the cryptic (bottom) 3’ ss for 7 alternative 3’ splicing events identified in sorted KPC-Sf3b1<sup>K700E/+</sup> tumor cells. (<bold>D</bold>) Venn-diagram depicting alternative 3’ splice events in the pan-cancer data-set (PSI &gt; 0.05 and p&lt;1<sup>–10</sup>) and sorted KPC-Sf3b1<sup>K700E/+</sup> tumor cells (PSI &gt; 0.1, p&lt;0.01). (<bold>E</bold>) Representative gel image (top) and NGS-results (bottom) of <italic>Map3k7</italic> cDNA isolated from sorted KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> tumor cells (n=4). The amplicon includes the 3’ splice site of exon 4 and 5, the upper band (114 bp) of the gel image represents the non-canonical transcript variant, the lower band (94 bp) represents the canonical isoform. Dashed line indicates cropping of gel image. (<bold>F</bold>) Representative gel image of RT-PCR amplicon of <italic>Map3k7</italic> cDNA isolated from WT and <italic>Sf3b1<sup>K700E/+</sup></italic> pancreata and from the indicated human cell lines. The upper band of the gel image represents the non-canonical transcript variant, the lower band represents the canonical isoform. The length of the amplicon derived from murine pancreas cells is 114 bp (canonical) and 137 bp (non-canonical) and from human cell lines 94 bp (canonical) and 114 bp (non-canonical).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>SF3B1-K700E induces aberrant splicing of MAP3K7 in human and mouse PDAC.</title><p>(<bold>A</bold>) Pan-cancer analysis of alternative splice-events identified in solid tumors carrying the <italic>SF3B1<sup>K700E</sup></italic> mutation (PSI &gt;0.05, FDR &lt;1<sup>–10</sup>). (<bold>B</bold>) Histogram displaying the distance of cryptic 3’ss from the adjacent canonical 3’ss on a logarithmic scale in solid tumors carrying the <italic>SF3B1<sup>K700E</sup></italic> mutation. (<bold>C</bold>) NGS-results of <italic>Map3k7</italic> cDNA isolated from WT and <italic>Sf3b1<sup>K700E/+</sup></italic> pancreas organoids (n=1). (<bold>D</bold>) RT-PCR amplicon of <italic>MAP3K7</italic> cDNA isolated from four human PDAC cell lines overexpressing wildtype SF3B1 (OE WT) or K700E-mutated SF3B1 (OE K700E). The amplicon includes the 3’ splice site of exon 4 and 5, the upper band (114 bp) of the gel image represents the non-canonical isoform, the lower band (94 bp) the canonical isoform. (<bold>E</bold>) RT-qPCR of <italic>Ppp2r5a</italic> expression in KPC (n=13) and KPC-Sf3b1<sup>K700E/+</sup> (n=12) cancer-derived organoid lines. Two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>F</bold>) RT-PCR amplicon of <italic>Ppp2r5a</italic> cDNA isolated from sorted KPC (n=3) and KPC-Sf3b1<sup>K700E/+</sup> (n=4), as well as WT and <italic>Sf3b1<sup>K700E/+</sup></italic> pancreas organoids. The amplicon includes the 3’ splice site of exon 4 and 5, whereby the length of the canonical isoform is 250 bp and the upper arrowhead represents the predicted size (265 bp) of the non-canonical isoform.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig4-figsupp1-v3.tif"/></fig></fig-group><p>Since <italic>Sf3b1<sup>K700E</sup></italic> dependent missplicing in <italic>MAP3K7</italic> was shown to result in reduced RNA and protein levels of MAP3K7 in leukaemia (<xref ref-type="bibr" rid="bib41">North et al., 2022</xref>), we hypothesized that the reduced responsiveness to TGF-β signalling in SF3B1<sup>K700E</sup> mutant pancreas cells is caused by lower MAP3K7 levels. Indeed, RT-qPCR and western blotting confirmed a reduction in MAP3K7 levels in vitro and in vivo in <italic>Sf3b1<sup>K700E</sup></italic> mutant pancreatic cells (<xref ref-type="fig" rid="fig5">Figure 5A–D</xref>). Next, we tested whether this reduction could explain the observed resistance to TGF-β in <italic>Sf3b1</italic>-mutant PDAC, and assessed the expression of EMT genes in TGF-β-treated KPC cells with a stable knock-down of MAP3K7 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Indeed, a decrease of <italic>Map3k7</italic> mRNA levels to 35% (SD ± 10%) led to a reduced expression in 7 out of 10 EMT genes (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Moreover, knocking down <italic>Map3k7</italic> in pre-cancerous pancreas organoids led to increased viability upon TGF-β1-treatment (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), and chemical inhibition of p38, one of the major effectors of MAP3K7, partially protected organoids against TGF-β1-induced cell death (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Further supporting our hypothesis that <italic>Sf3b1<sup>K700E</sup></italic> mediates resistance to TGF-β1 via MAP3K7, overexpression of the full-length isoform of MAP3K7 in TGF-β1-treated <italic>Sf3b1<sup>K700E</sup></italic> mutant organoids significantly decreased their viability (<xref ref-type="fig" rid="fig5">Figure 5H1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Reduction in <italic><named-content content-type="sequence">Map3k7</named-content></italic> lowers sensitivity to TGF-β1.</title><p>(<bold>A–C</bold>) RT-qPCR data showing <italic>Map3k7</italic> expression in KPC (n=13) and KPC-Sf3b1<sup>K700E/+</sup> (n=12) ex vivo tumor cultures (<bold>A</bold>), as well as WT (n=3) and Sf3b1<sup>K700E/+</sup> (n=4) pancreata (<bold>B</bold>) and organoid lines (<bold>C</bold>). For analysis, Ct-values of <italic>Map3k7</italic> were normalized to <italic>Actb</italic> and a two-tailed unpaired t-test was used to compute the indicated p-values. Data show mean and standard error of the mean in A, B and C. (<bold>D</bold>) Representative Western blot gel-image of MAP3K7 (molecular weight 78 kDa) and GAPDH (molecular weight 37 kDa) in WT and Sf3b1<sup>K700E/+</sup> organoids. (<bold>E</bold>) RT-qPCR analysis of <italic>Map3k7</italic> in cells transduced with a shMap3k7 compared to a control shRNA. Error bar represents SD, a two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>F</bold>) Quantification of viable WT and <italic>Sf3b1<sup>K700E/+</sup></italic> murine pancreatic duct organoids or WT transduced with control shRNA (shCtrl) or shRNA targeting <italic>Map3k7</italic> (shMap3k7). The organoids were exposed to 10 ng/ml TGF-β1 for 24 hr prior to analysis. The experiment was independently performed three times. Error bar represents SD, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>G</bold>) Viability of wildtype (WT) organoids cultured in medium containing 10 ng/ml TGF-β1, supplemented with chemical inhibitors targeting the indicated effectors of TGF-β1-signalling. Two independent experiments are summarized. Further details are provided in the methods section. (<bold>H</bold>) RT-qPCR analysis of <italic>Map3k7</italic> in cells transduced by lentivirus with an overexpression construct of <italic>Map3k7</italic>, compared to overexpression of GFP. Error bar represents SD, a two-tailed unpaired t-test was used to compute the indicated p-values. (<bold>I</bold>) Quantification of viable murine pancreatic duct organoids with stable overexpression of <italic>Map3k7</italic>, exposed to 10 ng/ml TGF-β1 for 96 hr. Data represents one organoid line per condition, the experiment was independently performed three times. Error bar represents SD, a two-tailed unpaired t-test was used to compute the indicated p-value. (<bold>J–K</bold>) Viability of human pancreatic duct H6c7 cells (<bold>J</bold>) or human pancreatic duct organoids (<bold>K</bold>) exposed to 10 ng/ml TGF-β1 with addition of the MAP3K7 inhibitor Takinib (TAKi, 5 μM) or DMSO. The viability was assessed after 48 hr of TGF-β1 treatment and normalized to cells grown in absence of TGF-β1. The experiment was independently performed four (<bold>J</bold>) or three (<bold>K</bold>) times. (<bold>L</bold>) Representative micrographs of wound healing assay of PANC-1 cells pre-treated with TGF-β1 (10 ng/ml) for 24 hr, with or without addition of 5 μM TAKi, at the indicated time points after performing the scratch. Scale bar is 50 μM. (<bold>M</bold>) Quantification of wound healing assay shown in (<bold>L</bold>). The experiment was independently performed three times. Error bar represents SD, a two-tailed unpaired t-test was used to compute the indicated p-values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Reduction in Map3k7 lowers sensitivity to TGF-β1.</title><p>(<bold>A</bold>) Western blot gel-image of <named-content content-type="sequence">MAP3K7</named-content> (molecular weight 78 kDa) and GAPDH (molecular weight 37 kDa) in a KPC cell line transduced with a control shRNA (shCtrl) or a shRNA targeting <named-content content-type="sequence">Map3k7</named-content> (shMap3k7). (<bold>B</bold>) RT-qPCR analysis of EMT genes displayed in <xref ref-type="fig" rid="fig2">Figure 2F</xref> in a KPC cell line transduced with a control shRNA (shCtrl) or a shRNA targeting <named-content content-type="sequence">Map3k7</named-content> (shMap3k7) treated with TGF-β1 (10 ng/ml) for 24 hr. The experiment was performed independently three times, error bar represents SD. (<bold>C</bold>) Organoid count normalized to untreated organoids of respective genotypes at passage 0. Duct organoids of indicated genotypes / treated with shRNA were exposed to 1 ng/ml TGF-β1 for 25 days. Data represents one organoid line per condition, the experiment was independently performed three times. Error bar represents SD, a one-way ANOVA was used to compute the indicated p-values.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-fig5-figsupp1-v3.tif"/></fig></fig-group><p>To further assess conservation of this mechanism between mice and humans, we next treated human pancreatic H6c7 cells as well as human pancreatic organoids before TGF-β1 exposure with Takinib (TAKi), a chemical inhibitor for <named-content content-type="sequence">MAP3K7</named-content>. In line with our results in murine cells, also in human pancreatic cells inhibition of <named-content content-type="sequence">MAP3K7</named-content> led to a significant increase in survival (<xref ref-type="fig" rid="fig5">Figure 5J and K</xref>). Moreover, conditioning human PANC-1 PDAC cells with TAKi prior to TGF-β1 exposure resulted in a significant decrease in migratory capacity in wound healing assays (<xref ref-type="fig" rid="fig5">Figure 5L and M</xref>). Taken together, our results suggest that <italic>Sf3b1<sup>K700E</sup></italic> mediates resistance of pancreatic epithelial cells to TGF-β1 via <named-content content-type="sequence">MAP3K7</named-content>, providing a potential mechanism for its role of in PDAC progression.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>While the roles of the most frequently mutated tumor driver genes in PDAC are well understood, oncogenes occurring at lower rates are less well studied (<xref ref-type="bibr" rid="bib21">International Cancer Genome Consortium et al., 2010</xref>). One of these genes is SF3B1, for which hotspot mutations occur in various tumor types, including PDAC. While the molecular function of oncogenic SF3B1 on RNA-splicing is well described, how deregulation of misspliced genes contribute to malignancy in different cancer entities is only partially understood. Previous studies have shown that in chronic lymphocytic leukaemia (CLL) SF3B1<sup>K700E</sup> leads to missplicing of <italic>PPP2R5A,</italic> which in turn stabilizes c-Myc and thereby promotes aggressiveness of tumor cells (<xref ref-type="bibr" rid="bib31">Liu et al., 2020a</xref>; <xref ref-type="bibr" rid="bib48">Yang et al., 2021</xref>). Furthermore, in breast cancer SF3B1<sup>K700E</sup> causes a tumor-promoting effect through missplicing in <italic><named-content content-type="sequence">MAP3K7</named-content></italic> and downstream activation of NF-κB-signalling (<xref ref-type="bibr" rid="bib33">Liu et al., 2021</xref>).</p><p>In our study we analysed the oncogenic function of SF3B1<sup>K700E</sup> in the context of PDAC. Using a conditional mouse model, we provide the first experimental evidence that <italic>Sf3b1<sup>K700E</sup></italic> indeed promotes PDAC progression. While the Sf3b1<sup>K700E</sup> mutation alone did not induce malignant transformation in the mouse pancreas, co-occurrence with KRAS and p53 mutations increased the severity of PDAC. Effects of SF3B1<sup>K700E</sup> were already observed during early stages of tumor progression and resulted in reduced expression of TGF-β-responsive EMT genes. Our experiments further revealed that SF3B1<sup>K700E</sup> reduces TGF-β-induced cell-death in pancreatic duct cell lines and organoids, providing a potential mechanism for the oncogenicity of SF3B1<sup>K700E</sup> in PDAC. In line with this hypothesis, pancreatic epithelial cells have previously been found to undergo lethal EMT when stimulated with TGF-β (<xref ref-type="bibr" rid="bib12">David et al., 2016</xref>), and acquiring TGF-β resistance is considered to be essential in early stages of PDAC tumorigenesis (<xref ref-type="bibr" rid="bib18">Hezel et al., 2012</xref>). Interestingly, akin to <italic>Sf3b1<sup>K700E</sup>,</italic> deletion of the vital TGF-β signalling component <italic>Smad4</italic> only triggered malignant transformation of the pancreas in combination with oncogenic Kras mutations (<xref ref-type="bibr" rid="bib4">Bardeesy et al., 2006b</xref>).</p><p>Splicing analysis of RNA-seq datasets from both murine and human cancers identified several genes that are misspliced in the SF3B1<sup>K700E</sup> background. Among the identified genes was <italic><named-content content-type="sequence">Map3k7</named-content>,</italic> which is known to mediate non-canonical TGF-β signaling (<xref ref-type="bibr" rid="bib27">Kim and Choi, 2012</xref>) and to induce EMT and apoptosis in TGF-β stimulated human mammary cells (<xref ref-type="bibr" rid="bib45">Tripathi et al., 2019</xref>). In this study, we show that reducing <italic><named-content content-type="sequence">Map3k7</named-content></italic> levels by shRNA mediated knockdown in pancreatic cell lines and organoids also impairs TGF-β-mediated EMT and cell death, although not to the same extend as <italic>Sf3b1<sup>K700E</sup></italic>. Thus, while aberrant splicing of other genes is likely also contributing to the observed resistance to TGF-β, our experiments indicate that TGF-β resistance in <italic>SF3B1<sup>K700E</sup></italic> mutant pancreatic ducts is at least partly mediated via <named-content content-type="sequence">MAP3K7</named-content>. Importantly, this hypothesis is also supported by previous studies, which demonstrated that SF3B1 mutations induce 3’ missplicing of <italic><named-content content-type="sequence">MAP3K7</named-content></italic> in various tumor entities (<xref ref-type="bibr" rid="bib6">Bondu et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib30">Lieu et al., 2022</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2020b</xref>; <xref ref-type="bibr" rid="bib47">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Zhang et al., 2019</xref>)<italic>,</italic> that aberrant splicing by SF3B1<sup>K700E</sup> reduces <named-content content-type="sequence">MAP3K7</named-content> protein levels (<xref ref-type="bibr" rid="bib41">North et al., 2022</xref>), and that <named-content content-type="sequence">MAP3K7</named-content> mediates TGF-β-induced EMT and apoptosis in mammary epithelial cells (<xref ref-type="bibr" rid="bib45">Tripathi et al., 2019</xref>). Notably, depending on the cellular context, <named-content content-type="sequence">MAP3K7</named-content> has been shown to exert pro-apoptotic stimuli through activation of MAPK p38 and Jun N-terminal kinase (JNK; <xref ref-type="bibr" rid="bib38">Mihaly et al., 2014</xref>), or anti-apoptotic stimuli through activation of the NF-κB pathway (<xref ref-type="bibr" rid="bib39">Mukhopadhyay and Lee, 2020</xref>). Thus, while our results show that SF3B1<sup>K700E</sup> mediated missplicing and inactivation of <named-content content-type="sequence">MAP3K7</named-content> protects pancreatic duct cells from TGF-β induced cell death, in other tissues or in combination with other mutations, the reduction of <named-content content-type="sequence">MAP3K7</named-content> levels by SF3B1<sup>K700E</sup> could trigger different phenotypic responses.</p><p>One limitation of our study is the lack of in vivo evidence supporting our hypothesis that SF3B1<sup>K700E</sup> promotes PDAC progression through <named-content content-type="sequence">MAP3K7</named-content> missplicing. We attempted to study the effect of altered <named-content content-type="sequence">MAP3K7</named-content> levels in an orthotopic PDAC transplantation model. However, we found that the model was not suitable for adressing this question, since introducing SF3B1<sup>K700E</sup> in KPC cells had no significant impact on tumor growth after transplantation. This outcome aligned with our expectations, given that KPC cells were isolated from fully established PDAC, where SF3B1<sup>K700E</sup> does not play the same role as in early-stage PDAC. Additional studies using autochthonous PDAC models, where <named-content content-type="sequence">Map3k7</named-content> levels are modulated in early stage KPC or KPC-<italic>Sf3b1<sup>K700E/+</sup></italic> tumors, would be required to foster in vivo evidence for the functional role of <named-content content-type="sequence">Map3k7</named-content> in SF3B1<sup>K700E</sup> mutant PDAC.</p><p>Taken together, this study provides a first demonstration that oncogenic SF3B1<sup>K700E</sup> promotes tumor progression in vivo in a mouse model for PDAC. Based on data from pancreatic organoids and cell lines, we further suggest that SF3B1<sup>K700E</sup> promotes PDAC progression by reducing tumor-suppressive TGF-β signalling through missplicing of <named-content content-type="sequence">MAP3K7</named-content>.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Animal models</title><p><italic>Sf3b1<sup>K700E/+</sup></italic> mice were a gift from E. A. Obeng (Dana-Farber Cancer Institute, Boston, USA) and B. L. Ebert (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA). <italic>LSL-Kras<sup>G12D/+</sup></italic>, <italic>LSL-Trp53<sup>R172H/+</sup></italic> and <italic>Ptf1a-Cre</italic> mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). All <italic>Sf3b1<sup>K700E/+</sup></italic> and KPC- <italic>Sf3b1<sup>K700E/+</sup></italic> mice were bred in a C57BL/6 J background, <italic>Sf3b1<sup>K700E/+</sup>; Kras<sup>G12D/+</sup></italic> mice were a C57BL/6J-BALB/c strain. Female and male mice were used for all experiments. Animals displaying dwarfism were excluded from analysis. The minimum of animals needed for the study was estimated by Fisher-Yates analysis. Due to the observed variance of the mouse model, more mice than initially estimated were used for the study. For the orthotopic transplantation models, KPC cells were derived from the autochthonous model described above by digestion of fully grown tumors and plating the digest in cell culture dishes. After multiple passages, KPC cells were grown to 80% confluency, and 10<sup>5</sup> cells were injected into the pancreas of BALB/cJ mice in matrigel, diluted in a 1:1 ratio with DMEM. 2Two weeks upon transplantation, mice were sacrificed. Mice were held in a specific-pathogen-free (SPF) animal facility at the ETH Phenomics Center EPIC (ETH Zurich, Switzerland). All animal experiments were conducted in accordance with the Swiss Federal Veterinary Office (BVET) guidelines (license no. ZH055/17).</p></sec><sec id="s4-2"><title>Cell lines</title><p>The human cell lines AsPC-1 (CRL-1682), BxPC-3 (CRL-1687), MIA-PaCa-2 (CRM-CRL-1420), PANC-1 (CRL-1469), PSN-1 (CRL-3211) and HEK293T (CRL-1573) cells were purchased from ATCC. H6c7 cells (ECA001-FP) were purchased from Kerafast. MIA-PaCa-2, PANC-1 and HEK293T cells were maintained in DMEM with 4.5 g/l D-Glucose and GlutaMAX (Gibco), supplemented with 10% fetal calf serum (FCS, Sigma-Aldrich) and 1% Penicillin- streptomycin (P/S, Invitrogen). AsPC-1, BxPC-3, and PSN-1 were cultured in RPMI1640 (Thermo Fisher), supplemented with 10% FCS and 1% P/S. H6c7 cells were cultured in Keratinocyte serum-free medium (Thermo Fisher), supplemented with recombinant EGF and bovine pituitary extract according to the manufacturer’s instructions (Thermo Fisher), as well as 100 μg/ml Primocin (Invivogen). Cell lines were regularly checked for mycoplasma-infections by Mycoplasma PCR-detection test (Thermo-Fisher).</p></sec><sec id="s4-3"><title>Murine organoids</title><p>Murine organoid lines from WT and <italic>Sf3b1<sup>K700E/+</sup></italic> animals (B6.129S4) were established as previously described (<xref ref-type="bibr" rid="bib5">Boj et al., 2015</xref>). Briefly, 43-week-old animals of both sexes were euthanized and their pancreata excised. The organs were dissected to thin pieces and digested in 4 mg/ml collagenase IV for 7 min at 37°C. Then, pancreatic ducts were manually picked under a light microscope and seeded in drops of growth factor reduced matrigel. In vitro activated (pre-) cancer organoid lines (<italic>Kras<sup>G12D/+</sup></italic>, <italic>Kras<sup>G12D/+</sup>; Sf3b1<sup>K700E/+</sup></italic>, <italic>Kras<sup>G12D/+</sup>; Trp53<sup>R172H/+</sup></italic> and <italic>Kras<sup>G12D/+</sup>; Trp53<sup>R172H/+</sup>; Sf3b1<sup>K700E/+</sup></italic>) were established from 8-week-old animals using the same protocol, except that recombination was achieved by delivering Cre-GFP by lentiviral transduction, followed by FACS sorting for GFP positive cells. Tumor-derived KPC and KPC-Sf3b1<sup>K700E/+</sup> organoid lines were established from solid tumors of KPC or KPC-Sf3b1<sup>K700E/+</sup> mice. Tumor tissue was digested for 2–3 hr in 4 mg/ml collagenase IV at 37°C, pelleted and seeded in drops of matrigel. The presence of the K700E mutation was validated with Sanger-sequencing on RNA level for each organoid line. Each organoid line was isolated from an individual mouse. Tumor-derived KPC and KPC-Sf3b1<sup>K700E/+</sup> organoid lines were additionally plated in regular cell culture dishes and grown as monolayer cell culture. Organoids were cultured in organoid medium (OM) composed of AdDMEM/F12 (Gibco) supplemented with GlutaMAX (Gibco), HEPES (Gibco), Penicillin-Streptomycin (Invitrogen), B27 (Gibco), 1.25 mM N-Acetyl-L-cysteine (Sigma), 10 nM Gastrin I (Sigma) and the growth factors: 100 ng/ml FGF10 (Peprotech), 50 ng/ml EGF (Peprotech), 100 ng/ml Noggin, 100 ng/ml RSPO-1 (Peprotech), and 10 mM Nicotinamide (Sigma). For the first week after duct isolation the culture medium was supplemented with 100 μg/ml Primocin (InvivoGen).</p></sec><sec id="s4-4"><title>Immunohistochemistry</title><p>Murine tissue specimens were dissected and fixed in 10% neutral buffered formalin for 48–72 hr. Thereafter, formalin was replaced with 70% ethanol before paraffin-embedding and sectioning at a thickness of 4  μm. Hematoxylin and eosin stainings were performed according to the manufacturer’s instructions. Anti-Cleaved Caspase 3 (Asp175) antibody (Cell Signaling Technology), anti-Amylase (100–4147) antibody (ThermoFisher), anti-Cytokeratin 19 (ab15463) antibody (ThermoFisher), anti-E-Cadherin (Clone 36) antibody (BD Biosciences), anti-FN-1 antibody (Chemicon), anti-MUC5AC (45M1) antibody (Novus Biologicals) and anti-TNC (Clone 578) antibody was used according to the manufacturer’s recommendations. TNC and amylase staining was quantified by calculating the average of Raw Int Density of 3–5 randomly chosen microscopy fields per specimen using ImageJ. CK19 and MUC5AC staining was quantified by counting stained cells of 3–5 randomly chosen microscopy fields per specimen. ADM structures were quantified by counting ADM structures of 5 microscopy fields per specimen of tissue not yet (or only minorly) progressed to PanINs. Luminal necrotic cells were defined as shed cells residing within the lumen of PanIN-lesions.</p></sec><sec id="s4-5"><title>Organoid growth assay</title><p>Growth of organoids was assessed with CellTiter-Glo 3D (Promega). For absolute quantification of ATP levels, standard curves with defined concentrations of ATP were used for every measurement according to the manufacturer’s instructions. As approximation of proliferation rate, the ratio of ATP concentrations at the indicated time points was calculated.</p></sec><sec id="s4-6"><title>Crystal violet assay</title><p>To measure proliferation of cell lines, 5000 cells were seeded per 96 wells. At the indicated time points, cells were stained with 0.5% (w/v) crystal violet (Sigma-Aldrich) dissolved in an aqueous solution with 20% Methanol (v/v). After washing, plates were allowed to air-dry and the crystal violet was dissolved in 10% acetic acid. Optical density was measured at 595 nM in an Infinite 200 plate reader (Tecan).</p></sec><sec id="s4-7"><title>Organoid viability assay</title><p>For short-term treatment, organoids were seeded as fragments in 10 μl of Matrigel and allowed to form spheres for 24 hr in regular organoid medium. Organoids were thereafter exposed to the indicated concentration of TGF-β1 (Thermo Fisher). To assess viability of the organoids, intact organoids were counted and compared to untreated organoids after 48 hr of TGF-β1-exposure. This method of quantification was validated by correlating counts of intact organoids with ATP levels as described above (data not shown). For long-term treatment, organoids were seeded as fragments in 40 μl of Matrigel. After allowing to form spheres for 24 hr, the indicated concentration of TGF-β1 was added. After 4 days of TGF-β1-treatment, matrigel-drops were imaged and the number of intact organoids was counted. Then, organoids were reseeded as fragments in normal organoid medium and TGF-β1 was added after 24 hr. Every 4th passage, organoids were split in a 1:1 ratio in the 1 ng/ml TGF-β1 condition.</p><p>Commercial cell lines were seeded and TGF-β1 was added at the indicated concentrations 12 hr after plating.</p></sec><sec id="s4-8"><title>Organoid invasion assay</title><p>Organoids were seeded at equal density in 40 μl of matrigel in 24-well plates. Twenty-four hr after seeding, organoid growth medium was supplemented with 10 ng/ml TGF-β1 (Thermo Fisher). Nienty-six hr after seeding, matrigel domes were detached by rinsing and the migrated organoids (i.e. cells attached to the cell culture dish) were stained by crystal violet. The fraction of attached organoids was calculated by dividing the number of attached organoids by the number of attached organoids plus the number of non-attached organoids (i.e. organoids residing in the matrigel dome).</p></sec><sec id="s4-9"><title>Cleaved-caspase 3/7 assay</title><p>Organoids were seeded 10 μl of Matrigel and allowed to form spheres for 24 hr in regular organoid medium. Organoids were thereafter exposed to 10 ng/ml TGF-β1 (Thermo Fisher) overnight. Cleavage of Caspase 3 and 7 was quantified by using Caspase-Glo 3/7 Assay System (Promega) according to the manufacturer’s instructions.</p></sec><sec id="s4-10"><title>Wound healing assay</title><p>8x10<sup>5</sup> human PANC-1 cells, overexpressing SF3B1-WT or SF3B1<sup>K700E</sup>, were seeded in six-well plates. Ten ng/ml TGF-β1 (and TAKi [5 μM] or DMSO [1:1000] in the respective experiments) was added overnight prior scratch formation with a 10 μl pipette tip. After scratch formation, fresh medium including TGF-β1 (and TAKi or DMSO) was added. 0 hr, 4 hr, and 7 hr after scratch formation, images were taken and the width of the scratch was analysed, performing four measures at standardized positions for each image using ImageJ / Fiji (NIH). To calculate the effect of TGF-β on gap closure in <xref ref-type="fig" rid="fig2">Figure 2J</xref>, distance of migration (gap width 0 hr after scratch formation – gap width 4 hr after scratch formation) of cells cultured with TGF-β was divided by distance of migration of cells cultured with control medium.</p></sec><sec id="s4-11"><title>Chemical inhibitors</title><p>The following chemical inhibitors targeting different effectors of the TGF-β-pathway were used: TGFbR-inhibitor A83-01 [50 nM] (Tocris Bioscience), p38-inhibitors SB202190 [10 μM] (Sigma-Aldrich) and SB203580 [10 μM] (Selleckchem), JNK-inhibitor SP600125 [25 μM] (Sigma-Aldrich), SMAD3-inhibitor SIS3 [10 μM] (Sigma-Aldrich) and <named-content content-type="sequence">MAP3K7</named-content>-inhbitor Takinib [5 μM] (Sigma-Aldrich). The inhibitors were added to the organoid medium directly after seeding.</p></sec><sec id="s4-12"><title>shRNA-mediated <italic>Map3k7</italic> knockdown</title><p>shRNA targeting murine <italic><named-content content-type="sequence">Map3k7</named-content></italic> was purchased from Sigma-Aldrich (TRCN0000022563). A pLKO.1-puro Non-Target shRNA was used as control. Lentivirus was produced by PEI-based transfection of HEK293T cells. Briefly, HEK293T cells were seeded at 70% confluency in 6-well plates, and the following plasmids were transfected: PAX2 plasmid (1100 ng), VSV-G plasmid (400 ng), cargo plasmid (1500 ng). Medium was changed 12 hr after transfection and the virus-containing supernatant collected after 36 hr. Organoids were dissociated into single cells by Tryp-LE treatment for 5 min at 37°C and consecutive mechanical disruption. After centrifugation, 10% Lentivirus-containing supernatant in organoid medium (v/v) was added to the cell suspension. After a 4–6 hr incubation at 37°C, cells were seeded in matrigel as described above. Organoids were selected in 2 ng/ml Puromycin after the first passage for at least 5 days.</p></sec><sec id="s4-13"><title>Overexpression of <italic>Map3k7</italic></title><p>Murine <italic><named-content content-type="sequence">Map3k7</named-content></italic> (full-length isoform) was amplified from cDNA of murine WT duct organoids and cloned into a Lenti-backbone (addgene #73582). Production of lentivirus and transduction of organoids was performed as described above. Organoids stably overexpressing GFP (addgene #17488) were used as experimental control.</p></sec><sec id="s4-14"><title>Overexpression of SF3B1-K700E</title><p>Codon-optimized human SF3B1-WT and SF3B1-K700E was derived from the plasmids pCDNA3.1-FLAG-SF3B1-WT (addgene #82576) and pCDNA3.1-FLAG-hSF3B1-K700E (addgene #82577) and cloned into a Lenti-backbone. The lentiviruses were produced as described above and used to transduce various cell lines. Puromycin-selection was used to select for transduced cells for at least two passages.</p></sec><sec id="s4-15"><title>RNA sequencing</title><sec id="s4-15-1"><title>Cell sorting and RNA extraction</title><p>Murine tumors were excised and digested for 2–3 hr in collagenase (4 mg/ml) at 37°C. After addition of fetal calf serum (FCS) to stop the digestion, cells were strained trough a 100 μm and a 70 μm cell strainer. Then, cells were washed twice in PBS + 2% FCS+2 mM EDTA and incubated with mouse FcBlock (BD Biosciences), Epcam-APC (CD326 Monoclonal Antibody (G8.8), APC, eBioscience, Thermo Fisher) and CD45-BV785 (Clone 30-F11, Biologened) antibodies for 30 min at 4°C. After washing, Epcam-positive-CD45-negative cells were sorted into lysis buffer with a BD FACSAriaIII Cell Sorter (BD Biosciences). Finally, RNA was extracted using NucleoSpin RNA XS kit (Macherey Nagel) according to the manufacturer’s instructions.</p></sec><sec id="s4-15-2"><title>Library preparation</title><p>The quantity and quality of the isolated RNA was determined with a Qubit (1.0) Fluorometer (Life Technologies, California, USA) and a Tapestion (Agilent, Waldbronn, Germany). The SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian (Clontech Laboratories, Inc, A Takara Bio Company,California, USA) was used in the succeeding steps. Briefly, total RNA samples (0.25–10 ng) were reverse-transcribed using random priming into double-stranded cDNA in the presence of a template switch oligo (TSO). When the reverse transcriptase reaches the 5’ end of the RNA fragment, the enzyme’s terminal transferase activity adds non-templated nucleotides to the 3’ end of the cDNA. The TSO pairs with the added non-templated nucleotide, enabling the reverse transcriptase to continue replicating to the end of the oligonucleotide. This results in a cDNA fragment that contains sequences derived from the random priming oligo and the TSO. PCR amplification using primers binding to these sequences can now be performed. The PCR adds full-length Illumina adapters, including the index for multiplexing. Ribosomal cDNA is cleaved by ZapR in the presence of the mammalian-specific R-Probes. Remaining fragments are enriched with a second round of PCR amplification using primers designed to match Illumina adapters.The quality and quantity of the enriched libraries were validated using Qubit (1.0) Fluorometer and the Tapestation (Agilent, Waldbronn, Germany). The product is a smear with an average fragment size of approximately 360 bp. The libraries were normalized to 10 nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20.</p></sec><sec id="s4-15-3"><title>Cluster generation and sequencing</title><p>The TruSeq SR Cluster Kit HS4000 or TruSeq PE Cluster Kit HS4000 (Illumina, Inc, California, USA) was used for cluster generation using 8 pM of pooled normalized libraries on the cBOT. Sequencing was performed on the Illumina HiSeq 4000 paired end at 2X126 bp or single end 126 bp using the TruSeq SBS Kit v4-HS (Illumina, Inc, California, USA).</p></sec><sec id="s4-15-4"><title>RNAseq data analysis</title><p>Adapters have been trimmed with trimmomatic (v0.35). Pairs for which both reads passed the trimming have been mapped to the murine genome using STAR (v2.7.0a) and indexed BAM files obtained with samtools (v1.9). Reads were counted with featureCounts from subread package (v1.5.0). The read counts have been processed in a statistical analysis using edgeR (v3.24.3), obtaining a list of genes ranked for differential expression by p-value and Benjamini-Hochberg adjusted p-value as the estimate of the false discovery rate. All data is summarized in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-15-5"><title>Gene set enrichment analysis</title><p>Gene set enrichment analysis (v.4.1.0, Broad Institute, MIT) was used to determine enriched gene sets in KPC or KPC-Sf3b1<sup>K700E/+</sup> tumor cells. Standard parameters of the software were used to perform the analysis. Molecular Signatures Database v7.4, Hallmark Gene Sets (H) was used to query enriched gene sets. The input gene expression matrix contained read-count information (count per million) of 21,633 genes.</p></sec><sec id="s4-15-6"><title>Alternative splicing analysis</title><p>We ran a 2-pass alignment of the fastq files using STAR v2.7 (<xref ref-type="bibr" rid="bib14">Dobin et al., 2013</xref>) using the GRCm38.p6 genome as reference. The gene annotation used was GENCODE v.m25. For gene expression quantification, we used a custom script, available at <ext-link ext-link-type="uri" xlink:href="https://github.com/ratschlab/gromics/">GitHub</ext-link> (copy archived at <xref ref-type="bibr" rid="bib25">Kahles, 2021</xref>); commit hash d074114f1d0a9f518c9cd039f68de0cdf8d583ff. SplAdder v.2.2 (<xref ref-type="bibr" rid="bib23">Kahles et al., 2016</xref>) was run to build splicing graphs and determine splice events. Differential splicing events were determined by calculating a log(psi +x) transformation of the percent spliced in (calculated as ratio of reads supporting the splice event over the number of reads supporting the alternate event). Splice events that did not show any variability over the samples were removed and missing values were mean imputed. After standardization, a two-sided t-test was used to calculate p-values of splice events differences between KPC and KPC-Sf3b1<sup>K700E</sup> mice. All data is summarized in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-15-7"><title>Motif analysis</title><p>Consensus 3’ ss motif in proximity of the canonical and the cryptic 3’ ss in sorted KPC-Sf3b1<sup>K700E/+</sup> tumor cells was assessed by query 30–40 bases spanning the respective 3’ss of the 7 main splice events for a motif using weblogo-sequence creator (<ext-link ext-link-type="uri" xlink:href="https://weblogo.berkeley.edu/logo.cgi">https://weblogo.berkeley.edu/logo.cgi</ext-link>).</p></sec><sec id="s4-15-8"><title>RT-PCR and quantitative RT-PCR (qPCR)</title><p>RNA-extraction was performed with QIAGEN RNeasy Mini Kit, and cDNA was generated with GoScript Reverse Transcriptase kit (Promega) according to the manufacturers’ instructions. RT-PCR was performed with GoTaq G2 Green Master Mix (Promega) and gene-specific primers. Amplicons were fractionated on 2% TBE gel (Life Technologies) supplemented with 0.01% GelRed (Biotium). For qPCR, 2 μL of 1:10-diluted cDNA was added to 8 μl of 5 x HOT FIREPol Evagreen qPCR Supermix (SolisBiodyne). Raw gel images can be found in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. RT-qPCR was performed with a LightCycler480 II (Roche). Relative gene expression was determined with the comparative CT method. Genes with a median CT value of more than 33 cycles and a difference of less than 3.3 cycles to the template control (H<sub>2</sub>O) were defined as not detectable. Sequences of all primers used in this study are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-15-9"><title>NGS-based isoform quantification of <italic>Map3k7</italic></title><p>Primers generating an amplicon including the exon 4 and exon 5 junction of Map3k7 cDNA were used. Briefly, a gene-specific amplicon was generated in a 20 μL reaction for 35 cycles with GoTaq G2 Green Master Mix (Promega). The PCR product was purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel). Thereafter, the isolated product was amplified for eight cycles using primers with sequencing adapters. After column-based isolation of the amplicon and quantification of DNA-yield using a Qubit 3.0 fluorometer and the dsDNA HS assay kit 392 (Thermo Fisher), paired-end sequencing was performed on an Illumina Miseq. The sequencing data was subsequently analyzed with CRISPResso2 (<xref ref-type="bibr" rid="bib10">Clement et al., 2019</xref>).</p></sec><sec id="s4-15-10"><title>Western blotting</title><p>Cells were lysed in RIPA buffer, supplemented with Protease Inhibitor (Cell Signaling Technologies) and PhosStop (Sigma-Aldrich) and centrifuged for 10 min at 21,000 <italic>g</italic>. The protein concentration of the supernatant was determined using Pierce BCA assay (ThermoFisher) and a standard curve of albumin. Then, samples were heated for 5’ at 95°C in Lämmli buffer and protein lysates were resolved on polyacrylamide Mini-PROTEAN TGX gels (Bio-Rad) and transferred onto nitrocellulose membrane by wet-transfer. The following antibodies were used for immunoblotting: Recombinant anti-GADPH (EPR16891, Abcam) and rabbit monoclonal anti-MAP3K7 (anti-TAK1, D94D7, Cell Signaling Technology) IRDye-conjugated secondary antibodies (donkey anti-goat: LI-COR cat. no. 926–32214; anti-rabbit: LI-COR cat. no. 926–68073) were used for signal detection by an Odyssey Imager (LI-COR) imaging system. Raw gel images can be found in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were conducted in accordance with the Swiss Federal Veterinary Office (BVET) guidelines (license no. ZH055/17).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Differential gene expression analysis of sorted KPC and KPC-Sf3b1<sup>K700E</sup> tumor cells, displaying logFC, logCPM, P-Value, False discovery rate (FDR) and EntrezID.</title></caption><media xlink:href="elife-80683-supp1-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Splicing analysis of indicated alternative splice events in sorted KPC and KPC-Sf3b1<sup>K700E</sup> tumor cells, displaying Ensembl ID, gene name, event positions, percent spliced in (delta psi), standard deviation, p-value and FDR.</title></caption><media xlink:href="elife-80683-supp2-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Name and nucleotide sequence of all primers used in the study.</title></caption><media xlink:href="elife-80683-supp3-v3.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Uncropped gel images of Western blot an RT-PCR experiments.</title></caption><media xlink:href="elife-80683-data1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80683-mdarchecklist1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The RNA sequencing raw data of sorted murine cancer cells was deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE203339. Splice analysis of human cancers was performed on a previously published dataset, accessible at <ext-link ext-link-type="uri" xlink:href="https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018">https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018</ext-link> (<xref ref-type="bibr" rid="bib24">Kahles et al., 2018</xref>). Material created in this study (i.e. primary cell lines, plasmids) are provided upon request and shall be directed at the corresponding author of this study (Prof. G. Schwank).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Simmler</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>RNA-seq of sorted KPC Sf3b1-K700E murine PDAC cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203339">GSE203339</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Kahles</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients</data-title><source>NCI Genomic Data Commons</source><pub-id pub-id-type="accession" xlink:href="https://gdc.cancer.gov/about-data/publications/PanCanAtlas-Splicing-2018">PanCanAtlas-Splicing-2018</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to E A Obeng (Dana-Farber Cancer Institute, Boston) and B L Ebert (Brigham and Women’s Hospital, Harvard Medical School, Boston) for providing the Sf3b1<sup>K700E/+</sup> mice used in our study. This work was supported by the Swiss National Science Foundation (grant number 185293 and 176317). The Aceto laboratory is supported by the European Research Council (101001652), the strategic focus area of Personalized Health and Related Technologies at ETH Zurich (PHRT-541), the Swiss National Science Foundation (212183), the Swiss Cancer League (KLS-4834-08-2019), the ETH Lymphoma Challenge (LC-02-22) and the ETH Zürich. TT, AK, KVL are supported by ETH core funding to GR.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsafadi</surname><given-names>S</given-names></name><name><surname>Houy</surname><given-names>A</given-names></name><name><surname>Battistella</surname><given-names>A</given-names></name><name><surname>Popova</surname><given-names>T</given-names></name><name><surname>Wassef</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>E</given-names></name><name><surname>Tirode</surname><given-names>F</given-names></name><name><surname>Constantinou</surname><given-names>A</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S</given-names></name><name><surname>Roman-Roman</surname><given-names>S</given-names></name><name><surname>Dutertre</surname><given-names>M</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10615</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10615</pub-id><pub-id pub-id-type="pmid">26842708</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>P</given-names></name><name><surname>Chang</surname><given-names>DK</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><name><surname>Johns</surname><given-names>AL</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Gingras</surname><given-names>MC</given-names></name><name><surname>Miller</surname><given-names>DK</given-names></name><name><surname>Christ</surname><given-names>AN</given-names></name><name><surname>Bruxner</surname><given-names>TJC</given-names></name><name><surname>Quinn</surname><given-names>MC</given-names></name><name><surname>Nourse</surname><given-names>C</given-names></name><name><surname>Murtaugh</surname><given-names>LC</given-names></name><name><surname>Harliwong</surname><given-names>I</given-names></name><name><surname>Idrisoglu</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>S</given-names></name><name><surname>Nourbakhsh</surname><given-names>E</given-names></name><name><surname>Wani</surname><given-names>S</given-names></name><name><surname>Fink</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>O</given-names></name><name><surname>Chin</surname><given-names>V</given-names></name><name><surname>Anderson</surname><given-names>MJ</given-names></name><name><surname>Kazakoff</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Newell</surname><given-names>F</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Wood</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Wilson</surname><given-names>PJ</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Kassahn</surname><given-names>KS</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Quek</surname><given-names>K</given-names></name><name><surname>Robertson</surname><given-names>A</given-names></name><name><surname>Pantano</surname><given-names>L</given-names></name><name><surname>Mincarelli</surname><given-names>L</given-names></name><name><surname>Sanchez</surname><given-names>LN</given-names></name><name><surname>Evers</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Pinese</surname><given-names>M</given-names></name><name><surname>Cowley</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Colvin</surname><given-names>EK</given-names></name><name><surname>Nagrial</surname><given-names>AM</given-names></name><name><surname>Humphrey</surname><given-names>ES</given-names></name><name><surname>Chantrill</surname><given-names>LA</given-names></name><name><surname>Mawson</surname><given-names>A</given-names></name><name><surname>Humphris</surname><given-names>J</given-names></name><name><surname>Chou</surname><given-names>A</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Scarlett</surname><given-names>CJ</given-names></name><name><surname>Pinho</surname><given-names>AV</given-names></name><name><surname>Giry-Laterriere</surname><given-names>M</given-names></name><name><surname>Rooman</surname><given-names>I</given-names></name><name><surname>Samra</surname><given-names>JS</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><name><surname>Lovell</surname><given-names>JA</given-names></name><name><surname>Merrett</surname><given-names>ND</given-names></name><name><surname>Toon</surname><given-names>CW</given-names></name><name><surname>Epari</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>NQ</given-names></name><name><surname>Barbour</surname><given-names>A</given-names></name><name><surname>Zeps</surname><given-names>N</given-names></name><name><surname>Moran-Jones</surname><given-names>K</given-names></name><name><surname>Jamieson</surname><given-names>NB</given-names></name><name><surname>Graham</surname><given-names>JS</given-names></name><name><surname>Duthie</surname><given-names>F</given-names></name><name><surname>Oien</surname><given-names>K</given-names></name><name><surname>Hair</surname><given-names>J</given-names></name><name><surname>Grützmann</surname><given-names>R</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Morgan</surname><given-names>RA</given-names></name><name><surname>Lawlor</surname><given-names>RT</given-names></name><name><surname>Corbo</surname><given-names>V</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Rusev</surname><given-names>B</given-names></name><name><surname>Capelli</surname><given-names>P</given-names></name><name><surname>Salvia</surname><given-names>R</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><name><surname>Munzy</surname><given-names>DM</given-names></name><name><surname>Fisher</surname><given-names>WE</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Pilarsky</surname><given-names>C</given-names></name><name><surname>Morton</surname><given-names>JP</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Bailey</surname><given-names>UMH</given-names></name><name><surname>Hofmann</surname><given-names>O</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic analyses identify molecular subtypes of pancreatic cancer</article-title><source>Nature</source><volume>531</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nature16965</pub-id><pub-id pub-id-type="pmid">26909576</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Aguirre</surname><given-names>AJ</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Cheng</surname><given-names>KH</given-names></name><name><surname>Lopez</surname><given-names>LV</given-names></name><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Mahmood</surname><given-names>U</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Redston</surname><given-names>MS</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006a</year><article-title>Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse</article-title><source>PNAS</source><volume>103</volume><fpage>5947</fpage><lpage>5952</lpage><pub-id pub-id-type="doi">10.1073/pnas.0601273103</pub-id><pub-id pub-id-type="pmid">16585505</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Cheng</surname><given-names>KH</given-names></name><name><surname>Berger</surname><given-names>JH</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Pahler</surname><given-names>J</given-names></name><name><surname>Olson</surname><given-names>P</given-names></name><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Horner</surname><given-names>J</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006b</year><article-title>Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer</article-title><source>Genes &amp; Development</source><volume>20</volume><fpage>3130</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1101/gad.1478706</pub-id><pub-id pub-id-type="pmid">17114584</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boj</surname><given-names>SF</given-names></name><name><surname>Hwang</surname><given-names>CI</given-names></name><name><surname>Baker</surname><given-names>LA</given-names></name><name><surname>Chio</surname><given-names>IIC</given-names></name><name><surname>Engle</surname><given-names>DD</given-names></name><name><surname>Corbo</surname><given-names>V</given-names></name><name><surname>Jager</surname><given-names>M</given-names></name><name><surname>Ponz-Sarvise</surname><given-names>M</given-names></name><name><surname>Tiriac</surname><given-names>H</given-names></name><name><surname>Spector</surname><given-names>MS</given-names></name><name><surname>Gracanin</surname><given-names>A</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>KH</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name><name><surname>Huch</surname><given-names>M</given-names></name><name><surname>Rivera</surname><given-names>KD</given-names></name><name><surname>Wilson</surname><given-names>JP</given-names></name><name><surname>Feigin</surname><given-names>ME</given-names></name><name><surname>Öhlund</surname><given-names>D</given-names></name><name><surname>Handly-Santana</surname><given-names>A</given-names></name><name><surname>Ardito-Abraham</surname><given-names>CM</given-names></name><name><surname>Ludwig</surname><given-names>M</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Alagesan</surname><given-names>B</given-names></name><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Yordanov</surname><given-names>GN</given-names></name><name><surname>Delcuze</surname><given-names>B</given-names></name><name><surname>Creighton</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Morsink</surname><given-names>FHM</given-names></name><name><surname>Molenaar</surname><given-names>IQ</given-names></name><name><surname>Borel Rinkes</surname><given-names>IH</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Nijman</surname><given-names>IJ</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>C</given-names></name><name><surname>Leach</surname><given-names>SD</given-names></name><name><surname>Pappin</surname><given-names>DJ</given-names></name><name><surname>Hammell</surname><given-names>M</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Basturk</surname><given-names>O</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Offerhaus</surname><given-names>GJ</given-names></name><name><surname>Vries</surname><given-names>RGJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Organoid models of human and mouse ductal pancreatic cancer</article-title><source>Cell</source><volume>160</volume><fpage>324</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.12.021</pub-id><pub-id pub-id-type="pmid">25557080</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bondu</surname><given-names>S</given-names></name><name><surname>Alary</surname><given-names>A-S</given-names></name><name><surname>Lefèvre</surname><given-names>C</given-names></name><name><surname>Houy</surname><given-names>A</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Lefebvre</surname><given-names>T</given-names></name><name><surname>Rombaut</surname><given-names>D</given-names></name><name><surname>Boussaid</surname><given-names>I</given-names></name><name><surname>Bousta</surname><given-names>A</given-names></name><name><surname>Guillonneau</surname><given-names>F</given-names></name><name><surname>Perrier</surname><given-names>P</given-names></name><name><surname>Alsafadi</surname><given-names>S</given-names></name><name><surname>Wassef</surname><given-names>M</given-names></name><name><surname>Margueron</surname><given-names>R</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Droin</surname><given-names>N</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Kaltenbach</surname><given-names>S</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Kubasch</surname><given-names>A-S</given-names></name><name><surname>Bouscary</surname><given-names>D</given-names></name><name><surname>Santini</surname><given-names>V</given-names></name><name><surname>Toma</surname><given-names>A</given-names></name><name><surname>Hunault</surname><given-names>M</given-names></name><name><surname>Stamatoullas</surname><given-names>A</given-names></name><name><surname>Gyan</surname><given-names>E</given-names></name><name><surname>Cluzeau</surname><given-names>T</given-names></name><name><surname>Platzbecker</surname><given-names>U</given-names></name><name><surname>Adès</surname><given-names>L</given-names></name><name><surname>Puy</surname><given-names>H</given-names></name><name><surname>Stern</surname><given-names>M-H</given-names></name><name><surname>Karim</surname><given-names>Z</given-names></name><name><surname>Mayeux</surname><given-names>P</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Kautz</surname><given-names>L</given-names></name><name><surname>Kosmider</surname><given-names>O</given-names></name><name><surname>Fontenay</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A variant erythroferrone disrupts iron homeostasis in <italic>SF3B1</italic>-mutated myelodysplastic syndrome</article-title><source>Science Translational Medicine</source><volume>11</volume><elocation-id>eaav5467</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aav5467</pub-id><pub-id pub-id-type="pmid">31292266</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulle</surname><given-names>A</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer</article-title><source>Signal Transduction and Targeted Therapy</source><volume>5</volume><elocation-id>249</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-00341-1</pub-id><pub-id pub-id-type="pmid">33122631</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canbezdi</surname><given-names>C</given-names></name><name><surname>Tarin</surname><given-names>M</given-names></name><name><surname>Houy</surname><given-names>A</given-names></name><name><surname>Bellanger</surname><given-names>D</given-names></name><name><surname>Popova</surname><given-names>T</given-names></name><name><surname>Stern</surname><given-names>MH</given-names></name><name><surname>Roman-Roman</surname><given-names>S</given-names></name><name><surname>Alsafadi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Functional and conformational impact of cancer-associated <italic>SF3B1</italic> mutations depends on the position and the charge of amino acid substitution</article-title><source>Computational and Structural Biotechnology Journal</source><volume>19</volume><fpage>1361</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.02.012</pub-id><pub-id pub-id-type="pmid">33777335</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>AY</given-names></name><name><surname>Zhou</surname><given-names>YJ</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Pobiarzyn</surname><given-names>PW</given-names></name><name><surname>Tishchenko</surname><given-names>P</given-names></name><name><surname>Shah</surname><given-names>KM</given-names></name><name><surname>Wheeler</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>YM</given-names></name><name><surname>Loria</surname><given-names>PM</given-names></name><name><surname>Loganzo</surname><given-names>F</given-names></name><name><surname>Woo</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response</article-title><source>The Journal of Biological Chemistry</source><volume>297</volume><elocation-id>101277</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101277</pub-id><pub-id pub-id-type="pmid">34619148</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Canver</surname><given-names>MC</given-names></name><name><surname>Gehrke</surname><given-names>JM</given-names></name><name><surname>Farouni</surname><given-names>R</given-names></name><name><surname>Hsu</surname><given-names>JY</given-names></name><name><surname>Cole</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name><name><surname>Joung</surname><given-names>JK</given-names></name><name><surname>Bauer</surname><given-names>DE</given-names></name><name><surname>Pinello</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CRISPResso2 provides accurate and rapid genome editing sequence analysis</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>224</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0032-3</pub-id><pub-id pub-id-type="pmid">30809026</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darman</surname><given-names>RB</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Agrawal</surname><given-names>AA</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Aird</surname><given-names>D</given-names></name><name><surname>Bailey</surname><given-names>SL</given-names></name><name><surname>Bhavsar</surname><given-names>EB</given-names></name><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>Colla</surname><given-names>S</given-names></name><name><surname>Corson</surname><given-names>L</given-names></name><name><surname>Feala</surname><given-names>J</given-names></name><name><surname>Fekkes</surname><given-names>P</given-names></name><name><surname>Ichikawa</surname><given-names>K</given-names></name><name><surname>Keaney</surname><given-names>GF</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Kunii</surname><given-names>K</given-names></name><name><surname>MacKenzie</surname><given-names>C</given-names></name><name><surname>Matijevic</surname><given-names>M</given-names></name><name><surname>Mizui</surname><given-names>Y</given-names></name><name><surname>Myint</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Puyang</surname><given-names>X</given-names></name><name><surname>Selvaraj</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>MP</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name><name><surname>Warmuth</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer-Associated SF3B1 Hotspot mutations induce Cryptic 3’ splice site selection through use of a different branch point</article-title><source>Cell Reports</source><volume>13</volume><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.053</pub-id><pub-id pub-id-type="pmid">26565915</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>CJ</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Iacobuzio-Donahue</surname><given-names>CA</given-names></name><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TGF-β Tumor Suppression through a Lethal EMT</article-title><source>Cell</source><volume>164</volume><fpage>1015</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.01.009</pub-id><pub-id pub-id-type="pmid">26898331</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBoever</surname><given-names>C</given-names></name><name><surname>Ghia</surname><given-names>EM</given-names></name><name><surname>Shepard</surname><given-names>PJ</given-names></name><name><surname>Rassenti</surname><given-names>L</given-names></name><name><surname>Barrett</surname><given-names>CL</given-names></name><name><surname>Jepsen</surname><given-names>K</given-names></name><name><surname>Jamieson</surname><given-names>CHM</given-names></name><name><surname>Carson</surname><given-names>D</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><name><surname>Frazer</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcriptome sequencing reveals potential mechanism of cryptic 3’ splice site selection in SF3B1-mutated cancers</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004105</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004105</pub-id><pub-id pub-id-type="pmid">25768983</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>SF3B1</italic> mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients</article-title><source>Oncotarget</source><volume>8</volume><fpage>115018</fpage><lpage>115027</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22983</pub-id><pub-id pub-id-type="pmid">29383138</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furney</surname><given-names>SJ</given-names></name><name><surname>Pedersen</surname><given-names>M</given-names></name><name><surname>Gentien</surname><given-names>D</given-names></name><name><surname>Dumont</surname><given-names>AG</given-names></name><name><surname>Rapinat</surname><given-names>A</given-names></name><name><surname>Desjardins</surname><given-names>L</given-names></name><name><surname>Turajlic</surname><given-names>S</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S</given-names></name><name><surname>de la Grange</surname><given-names>P</given-names></name><name><surname>Roman-Roman</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>M-H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>SF3B1 mutations are associated with alternative splicing in uveal melanoma</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>1122</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0330</pub-id><pub-id pub-id-type="pmid">23861464</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández</surname><given-names>J</given-names></name><name><surname>Bechara</surname><given-names>E</given-names></name><name><surname>Schlesinger</surname><given-names>D</given-names></name><name><surname>Delgado</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>L</given-names></name><name><surname>Valcárcel</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor suppressor properties of the splicing regulatory factor RBM10</article-title><source>RNA Biology</source><volume>13</volume><fpage>466</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1080/15476286.2016.1144004</pub-id><pub-id pub-id-type="pmid">26853560</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Zimmerman</surname><given-names>SM</given-names></name><name><surname>Contino</surname><given-names>G</given-names></name><name><surname>Alagesan</surname><given-names>B</given-names></name><name><surname>O’Dell</surname><given-names>MR</given-names></name><name><surname>Rivera</surname><given-names>LB</given-names></name><name><surname>Harper</surname><given-names>J</given-names></name><name><surname>Lonning</surname><given-names>S</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression</article-title><source>Cancer Research</source><volume>72</volume><fpage>4840</fpage><lpage>4845</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0634</pub-id><pub-id pub-id-type="pmid">22787119</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hingorani</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Multani</surname><given-names>AS</given-names></name><name><surname>Combs</surname><given-names>C</given-names></name><name><surname>Deramaudt</surname><given-names>TB</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</article-title><source>Cancer Cell</source><volume>7</volume><fpage>469</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.04.023</pub-id><pub-id pub-id-type="pmid">15894267</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Adsay</surname><given-names>NV</given-names></name><name><surname>Albores-Saavedra</surname><given-names>J</given-names></name><name><surname>Anver</surname><given-names>MR</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Boivin</surname><given-names>GP</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Furukawa</surname><given-names>T</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Klimstra</surname><given-names>DS</given-names></name><name><surname>Kloppel</surname><given-names>G</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Longnecker</surname><given-names>DS</given-names></name><name><surname>Luttges</surname><given-names>J</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Offerhaus</surname><given-names>GJA</given-names></name><name><surname>Pérez-Gallego</surname><given-names>L</given-names></name><name><surname>Redston</surname><given-names>M</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations</article-title><source>Cancer Research</source><volume>66</volume><fpage>95</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2168</pub-id><pub-id pub-id-type="pmid">16397221</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Cancer Genome Consortium</collab><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><name><surname>Artez</surname><given-names>A</given-names></name><name><surname>Barker</surname><given-names>AD</given-names></name><name><surname>Bell</surname><given-names>C</given-names></name><name><surname>Bernabé</surname><given-names>RR</given-names></name><name><surname>Bhan</surname><given-names>MK</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Eerola</surname><given-names>I</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Guttmacher</surname><given-names>A</given-names></name><name><surname>Guyer</surname><given-names>M</given-names></name><name><surname>Hemsley</surname><given-names>FM</given-names></name><name><surname>Jennings</surname><given-names>JL</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Klatt</surname><given-names>P</given-names></name><name><surname>Kolar</surname><given-names>P</given-names></name><name><surname>Kusada</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name><name><surname>Laplace</surname><given-names>F</given-names></name><name><surname>Youyong</surname><given-names>L</given-names></name><name><surname>Nettekoven</surname><given-names>G</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>TS</given-names></name><name><surname>Remacle</surname><given-names>J</given-names></name><name><surname>Schafer</surname><given-names>AJ</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Vockley</surname><given-names>JG</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yuen</surname><given-names>MMF</given-names></name><name><surname>Knoppers</surname><given-names>BM</given-names></name><name><surname>Bobrow</surname><given-names>M</given-names></name><name><surname>Cambon-Thomsen</surname><given-names>A</given-names></name><name><surname>Dressler</surname><given-names>LG</given-names></name><name><surname>Dyke</surname><given-names>SOM</given-names></name><name><surname>Joly</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Kennedy</surname><given-names>KL</given-names></name><name><surname>Nicolás</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>MJ</given-names></name><name><surname>Rial-Sebbag</surname><given-names>E</given-names></name><name><surname>Romeo-Casabona</surname><given-names>CM</given-names></name><name><surname>Shaw</surname><given-names>KM</given-names></name><name><surname>Wallace</surname><given-names>S</given-names></name><name><surname>Wiesner</surname><given-names>GL</given-names></name><name><surname>Zeps</surname><given-names>N</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Chabannon</surname><given-names>C</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Clément</surname><given-names>B</given-names></name><name><surname>de Alava</surname><given-names>E</given-names></name><name><surname>Degos</surname><given-names>F</given-names></name><name><surname>Ferguson</surname><given-names>ML</given-names></name><name><surname>Geary</surname><given-names>P</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Johns</surname><given-names>AL</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Sarin</surname><given-names>R</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>van de Vijver</surname><given-names>M</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Bayés</surname><given-names>M</given-names></name><name><surname>Botwell</surname><given-names>DDL</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Majumder</surname><given-names>P</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Ning</surname><given-names>Z</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Swerdlow</surname><given-names>H</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Xue</surname><given-names>HH</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Hubbard</surname><given-names>TJ</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>SM</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Muthuswamy</surname><given-names>L</given-names></name><name><surname>Ouellette</surname><given-names>BFF</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Quesada</surname><given-names>V</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJ</given-names></name><name><surname>Joly</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>SM</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name><name><surname>Ouellette</surname><given-names>BFF</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Kennedy</surname><given-names>KL</given-names></name><name><surname>Axton</surname><given-names>M</given-names></name><name><surname>Dyke</surname><given-names>SOM</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Gunter</surname><given-names>C</given-names></name><name><surname>Guyer</surname><given-names>M</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Miller</surname><given-names>LJ</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Shaw</surname><given-names>KM</given-names></name><name><surname>Kasprzyk</surname><given-names>A</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Haider</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yung</surname><given-names>CK</given-names></name><name><surname>Cros</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Gnaneshan</surname><given-names>S</given-names></name><name><surname>Guberman</surname><given-names>J</given-names></name><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Bobrow</surname><given-names>M</given-names></name><name><surname>Chalmers</surname><given-names>DRC</given-names></name><name><surname>Hasel</surname><given-names>KW</given-names></name><name><surname>Joly</surname><given-names>Y</given-names></name><name><surname>Kaan</surname><given-names>TSH</given-names></name><name><surname>Kennedy</surname><given-names>KL</given-names></name><name><surname>Knoppers</surname><given-names>BM</given-names></name><name><surname>Lowrance</surname><given-names>WW</given-names></name><name><surname>Masui</surname><given-names>T</given-names></name><name><surname>Nicolás</surname><given-names>P</given-names></name><name><surname>Rial-Sebbag</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>LL</given-names></name><name><surname>Vergely</surname><given-names>C</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Bowtell</surname><given-names>DDL</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>deFazio</surname><given-names>A</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D</given-names></name><name><surname>Gardiner</surname><given-names>BB</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Tempero</surname><given-names>MA</given-names></name><name><surname>Waddell</surname><given-names>NJ</given-names></name><name><surname>Wilson</surname><given-names>PJ</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Tsao</surname><given-names>M-S</given-names></name><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Thayer</surname><given-names>S</given-names></name><name><surname>Muthuswamy</surname><given-names>L</given-names></name><name><surname>Shazand</surname><given-names>K</given-names></name><name><surname>Beck</surname><given-names>T</given-names></name><name><surname>Sam</surname><given-names>M</given-names></name><name><surname>Timms</surname><given-names>L</given-names></name><name><surname>Ballin</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xing</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Tost</surname><given-names>J</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Holcatova</surname><given-names>I</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Brazma</surname><given-names>A</given-names></name><name><surname>Egevard</surname><given-names>L</given-names></name><name><surname>Prokhortchouk</surname><given-names>E</given-names></name><name><surname>Banks</surname><given-names>RE</given-names></name><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Cambon-Thomsen</surname><given-names>A</given-names></name><name><surname>Viksna</surname><given-names>J</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name><name><surname>Skryabin</surname><given-names>K</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Thoms</surname><given-names>G</given-names></name><name><surname>van de Vijver</surname><given-names>M</given-names></name><name><surname>van’t Veer</surname><given-names>L</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name><name><surname>Blanche</surname><given-names>H</given-names></name><name><surname>Boucher</surname><given-names>P</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Chabannon</surname><given-names>C</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Masson-Jacquemier</surname><given-names>JD</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Pauporté</surname><given-names>I</given-names></name><name><surname>Pivot</surname><given-names>X</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Tabone</surname><given-names>E</given-names></name><name><surname>Theillet</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Tost</surname><given-names>J</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Bioulac-Sage</surname><given-names>P</given-names></name><name><surname>Clément</surname><given-names>B</given-names></name><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Degos</surname><given-names>F</given-names></name><name><surname>Franco</surname><given-names>D</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Gut</surname><given-names>M</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Samuel</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Landgraf</surname><given-names>P</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Pfister</surname><given-names>S</given-names></name><name><surname>Radlwimmer</surname><given-names>B</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name><name><surname>Majumder</surname><given-names>PP</given-names></name><name><surname>Sarin</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>TS</given-names></name><name><surname>Bhan</surname><given-names>MK</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Pederzoli</surname><given-names>P</given-names></name><name><surname>Lawlor</surname><given-names>RA</given-names></name><name><surname>Delledonne</surname><given-names>M</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Gress</surname><given-names>T</given-names></name><name><surname>Klimstra</surname><given-names>D</given-names></name><name><surname>Zamboni</surname><given-names>G</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Kusada</surname><given-names>J</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>de Sanjosé</surname><given-names>S</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name><name><surname>González-Díaz</surname><given-names>M</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Jares</surname><given-names>P</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><name><surname>Himmelbauer</surname><given-names>H</given-names></name><name><surname>Quesada</surname><given-names>V</given-names></name><name><surname>Bea</surname><given-names>S</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>van de Vijver</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Masson-Jacquemier</surname><given-names>JD</given-names></name><name><surname>Aparicio</surname><given-names>S</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>van’t Veer</surname><given-names>L</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Barker</surname><given-names>AD</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>Ferguson</surname><given-names>ML</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gunter</surname><given-names>C</given-names></name><name><surname>Guttmacher</surname><given-names>A</given-names></name><name><surname>Guyer</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Penny</surname><given-names>R</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Shaw</surname><given-names>KM</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Vockley</surname><given-names>JG</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Knoppers</surname><given-names>BM</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Anderson</surname><given-names>W</given-names></name><name><surname>Barker</surname><given-names>AD</given-names></name><name><surname>Bell</surname><given-names>C</given-names></name><name><surname>Bobrow</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>W</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Guyer</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Hubbard</surname><given-names>TJ</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name><name><surname>Kennedy</surname><given-names>KL</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Majumder</surname><given-names>P</given-names></name><name><surname>Marra</surname><given-names>M</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Schafer</surname><given-names>AJ</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Wainwright</surname><given-names>BJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>International network of cancer genome projects</article-title><source>Nature</source><volume>464</volume><fpage>993</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1038/nature08987</pub-id><pub-id pub-id-type="pmid">20393554</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Je</surname><given-names>EM</given-names></name><name><surname>Yoo</surname><given-names>NJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors</article-title><source>International Journal of Cancer</source><volume>133</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1002/ijc.28011</pub-id><pub-id pub-id-type="pmid">23280334</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahles</surname><given-names>A</given-names></name><name><surname>Ong</surname><given-names>CS</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Rätsch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data</article-title><source>Bioinformatics</source><volume>32</volume><fpage>1840</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw076</pub-id><pub-id pub-id-type="pmid">26873928</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahles</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>KV</given-names></name><name><surname>Toussaint</surname><given-names>NC</given-names></name><name><surname>Hüser</surname><given-names>M</given-names></name><name><surname>Stark</surname><given-names>SG</given-names></name><name><surname>Sachsenberg</surname><given-names>T</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Kohlbacher</surname><given-names>O</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><collab>Cancer Genome Atlas Research Network</collab><name><surname>Rätsch</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive analysis of alternative splicing across Tumors from 8,705 Patients</article-title><source>Cancer Cell</source><volume>34</volume><fpage>211</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.07.001</pub-id><pub-id pub-id-type="pmid">30078747</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Kahles</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Gromics</data-title><version designator="swh:1:rev:aafd8505d2763978b79c07228aa40819efd2fa74">swh:1:rev:aafd8505d2763978b79c07228aa40819efd2fa74</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:cf9b37f8df816d1d5c7104da057109d7657899bd;origin=https://github.com/ratschlab/gromics;visit=swh:1:snp:b71b438361b492fffb4ac68d70002fdd2ddc7073;anchor=swh:1:rev:aafd8505d2763978b79c07228aa40819efd2fa74">https://archive.softwareheritage.org/swh:1:dir:cf9b37f8df816d1d5c7104da057109d7657899bd;origin=https://github.com/ratschlab/gromics;visit=swh:1:snp:b71b438361b492fffb4ac68d70002fdd2ddc7073;anchor=swh:1:rev:aafd8505d2763978b79c07228aa40819efd2fa74</ext-link></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesarwani</surname><given-names>AK</given-names></name><name><surname>Ramirez</surname><given-names>O</given-names></name><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Murthy</surname><given-names>T</given-names></name><name><surname>Minella</surname><given-names>AC</given-names></name><name><surname>Pillai</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3’ splice sites within RNA secondary structures</article-title><source>Oncogene</source><volume>36</volume><fpage>1123</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.279</pub-id><pub-id pub-id-type="pmid">27524419</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SI</given-names></name><name><surname>Choi</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TGF-β-activated kinase-1: New insights into the mechanism of TGF-β signaling and kidney disease</article-title><source>Kidney Research and Clinical Practice</source><volume>31</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.krcp.2012.04.322</pub-id><pub-id pub-id-type="pmid">26889415</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Rosenblum</surname><given-names>JS</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Somatic SF3B1 hotspot mutation in prolactinomas</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2506</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16052-8</pub-id><pub-id pub-id-type="pmid">32427851</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>R</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation</article-title><source>Journal of Biochemistry</source><volume>170</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1093/jb/mvab023</pub-id><pub-id pub-id-type="pmid">33751071</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieu</surname><given-names>YK</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Penson</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2111703119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2111703119</pub-id><pub-id pub-id-type="pmid">34930825</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yoshimi</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Chun-Wei Lee</surname><given-names>S</given-names></name><name><surname>Ki</surname><given-names>M</given-names></name><name><surname>Bitner</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Mato</surname><given-names>AR</given-names></name><name><surname>Ruvolo</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>G</given-names></name><name><surname>Pasqualucci</surname><given-names>L</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Mutations in the RNA Splicing Factor SF3B1 promote Tumorigenesis through MYC stabilization</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>806</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1330</pub-id><pub-id pub-id-type="pmid">32188705</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Perea-Chamblee</surname><given-names>TE</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Pan-cancer analysis identifies mutations in <italic>SUGP1</italic> that recapitulate mutant SF3B1 splicing dysregulation</article-title><source>PNAS</source><volume>117</volume><fpage>10305</fpage><lpage>10312</lpage><pub-id pub-id-type="doi">10.1073/pnas.1922622117</pub-id><pub-id pub-id-type="pmid">32332164</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ki</surname><given-names>M</given-names></name><name><surname>Erickson</surname><given-names>C</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Chandarlapaty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e138315</elocation-id><pub-id pub-id-type="doi">10.1172/JCI138315</pub-id><pub-id pub-id-type="pmid">33031100</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maguire</surname><given-names>SL</given-names></name><name><surname>Leonidou</surname><given-names>A</given-names></name><name><surname>Wai</surname><given-names>P</given-names></name><name><surname>Marchiò</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>CKY</given-names></name><name><surname>Sapino</surname><given-names>A</given-names></name><name><surname>Salomon</surname><given-names>AV</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Weigelt</surname><given-names>B</given-names></name><name><surname>Natrajan</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SF3B1 mutations constitute a novel therapeutic target in breast cancer</article-title><source>The Journal of Pathology</source><volume>235</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1002/path.4483</pub-id><pub-id pub-id-type="pmid">25424858</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marino</surname><given-names>S</given-names></name><name><surname>Vooijs</surname><given-names>M</given-names></name><name><surname>van Der Gulden</surname><given-names>H</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Berns</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">10783170</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massagué</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TGFβ in Cancer</article-title><source>Cell</source><volume>134</volume><fpage>215</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.07.001</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>YX</given-names></name><name><surname>Gu</surname><given-names>DL</given-names></name><name><surname>Zhu</surname><given-names>HC</given-names></name><name><surname>Zhu</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>JH</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>JZ</given-names></name><name><surname>Shao</surname><given-names>CL</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>SF3B1</italic> mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients</article-title><source>Annals of Translational Medicine</source><volume>7</volume><elocation-id>176</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2019.03.63</pub-id><pub-id pub-id-type="pmid">31168457</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihaly</surname><given-names>SR</given-names></name><name><surname>Ninomiya-Tsuji</surname><given-names>J</given-names></name><name><surname>Morioka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TAK1 control of cell death</article-title><source>Cell Death and Differentiation</source><volume>21</volume><fpage>1667</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.123</pub-id><pub-id pub-id-type="pmid">25146924</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukhopadhyay</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multifaceted roles of TAK1 signaling in cancer</article-title><source>Oncogene</source><volume>39</volume><fpage>1402</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-1088-8</pub-id><pub-id pub-id-type="pmid">31695153</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mupo</surname><given-names>A</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Sathiaseelan</surname><given-names>V</given-names></name><name><surname>Pance</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Agrawal</surname><given-names>AA</given-names></name><name><surname>Iorio</surname><given-names>F</given-names></name><name><surname>Bautista</surname><given-names>R</given-names></name><name><surname>Pacharne</surname><given-names>S</given-names></name><name><surname>Tzelepis</surname><given-names>K</given-names></name><name><surname>Manes</surname><given-names>N</given-names></name><name><surname>Wright</surname><given-names>P</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Kent</surname><given-names>DG</given-names></name><name><surname>Campbell</surname><given-names>PC</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Bolli</surname><given-names>N</given-names></name><name><surname>Vassiliou</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts</article-title><source>Leukemia</source><volume>31</volume><fpage>720</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1038/leu.2016.251</pub-id><pub-id pub-id-type="pmid">27604819</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>K</given-names></name><name><surname>Benbarche</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Pangallo</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Bewersdorf</surname><given-names>JP</given-names></name><name><surname>Stanley</surname><given-names>RF</given-names></name><name><surname>Erickson</surname><given-names>C</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Pineda</surname><given-names>JMB</given-names></name><name><surname>Thomas</surname><given-names>JD</given-names></name><name><surname>Polaski</surname><given-names>JT</given-names></name><name><surname>Belleville</surname><given-names>AE</given-names></name><name><surname>Gabel</surname><given-names>AM</given-names></name><name><surname>Udy</surname><given-names>DB</given-names></name><name><surname>Humbert</surname><given-names>O</given-names></name><name><surname>Kiem</surname><given-names>HP</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells</article-title><source>Nature Biotechnology</source><volume>40</volume><fpage>1103</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01224-2</pub-id><pub-id pub-id-type="pmid">35241838</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeng</surname><given-names>EA</given-names></name><name><surname>Chappell</surname><given-names>RJ</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>MC</given-names></name><name><surname>Campagna</surname><given-names>DR</given-names></name><name><surname>Schmidt</surname><given-names>PJ</given-names></name><name><surname>Schneider</surname><given-names>RK</given-names></name><name><surname>Lord</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gambe</surname><given-names>RG</given-names></name><name><surname>McConkey</surname><given-names>ME</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Mullally</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Physiologic Expression of Sf3b1(K700E) causes impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation</article-title><source>Cancer Cell</source><volume>30</volume><fpage>404</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.08.006</pub-id><pub-id pub-id-type="pmid">27622333</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast</article-title><source>Modern Pathology</source><volume>33</volume><fpage>1945</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1038/s41379-020-0554-8</pub-id><pub-id pub-id-type="pmid">32358590</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>AD</given-names></name><name><surname>Soulette</surname><given-names>CM</given-names></name><name><surname>van Baren</surname><given-names>MJ</given-names></name><name><surname>Hart</surname><given-names>K</given-names></name><name><surname>Hrabeta-Robinson</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1438</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15171-6</pub-id><pub-id pub-id-type="pmid">32188845</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Shin</surname><given-names>JH</given-names></name><name><surname>Stuelten</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance</article-title><source>Oncogene</source><volume>38</volume><fpage>3185</fpage><lpage>3200</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0655-8</pub-id><pub-id pub-id-type="pmid">30626936</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahl</surname><given-names>MC</given-names></name><name><surname>Will</surname><given-names>CL</given-names></name><name><surname>Lührmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The spliceosome: design principles of a dynamic RNP machine</article-title><source>Cell</source><volume>136</volume><fpage>701</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.009</pub-id><pub-id pub-id-type="pmid">19239890</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Gambe</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Hergert</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>SS</given-names></name><name><surname>Levin</surname><given-names>JZ</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Buonamici</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Chau</surname><given-names>KF</given-names></name><name><surname>Cibulskis</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Rassenti</surname><given-names>LZ</given-names></name><name><surname>Ghia</surname><given-names>EM</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><name><surname>Fernandes</surname><given-names>S</given-names></name><name><surname>Bloch</surname><given-names>DB</given-names></name><name><surname>Kotliar</surname><given-names>D</given-names></name><name><surname>Landau</surname><given-names>DA</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Reed</surname><given-names>R</given-names></name><name><surname>DeLuca</surname><given-names>DS</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Meyerson</surname><given-names>MM</given-names></name><name><surname>Kharchenko</surname><given-names>PV</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptomic characterization of SF3B1 mutation reveals Its Pleiotropic effects in Chronic Lymphocytic Leukemia</article-title><source>Cancer Cell</source><volume>30</volume><fpage>750</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.005</pub-id><pub-id pub-id-type="pmid">27818134</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J-Y</given-names></name><name><surname>Huo</surname><given-names>Y-M</given-names></name><name><surname>Yang</surname><given-names>M-W</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D-J</given-names></name><name><surname>Fu</surname><given-names>X-L</given-names></name><name><surname>Tao</surname><given-names>L-Y</given-names></name><name><surname>He</surname><given-names>R-Z</given-names></name><name><surname>Zhang</surname><given-names>J-F</given-names></name><name><surname>Hua</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>S-H</given-names></name><name><surname>Sun</surname><given-names>Y-W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis</article-title><source>Molecular Oncology</source><volume>15</volume><fpage>3076</fpage><lpage>3090</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12970</pub-id><pub-id pub-id-type="pmid">33932092</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Gambe</surname><given-names>RG</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Martinez</surname><given-names>AZ</given-names></name><name><surname>Cartun</surname><given-names>ZJ</given-names></name><name><surname>Regis</surname><given-names>FFD</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Herman</surname><given-names>SEM</given-names></name><name><surname>Ten Hacken</surname><given-names>E</given-names></name><name><surname>Taylor-Weiner</surname><given-names>A</given-names></name><name><surname>Rassenti</surname><given-names>LZ</given-names></name><name><surname>Ghia</surname><given-names>EM</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><name><surname>Obeng</surname><given-names>EA</given-names></name><name><surname>Cibulskis</surname><given-names>CL</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Campagna</surname><given-names>DR</given-names></name><name><surname>Fleming</surname><given-names>MD</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Wiestner</surname><given-names>A</given-names></name><name><surname>Leshchiner</surname><given-names>I</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Reed</surname><given-names>R</given-names></name><name><surname>Carrasco</surname><given-names>RD</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion</article-title><source>Cancer Cell</source><volume>35</volume><fpage>283</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.12.013</pub-id><pub-id pub-id-type="pmid">30712845</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Sato-Otsubo</surname><given-names>A</given-names></name><name><surname>Kon</surname><given-names>A</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Chalkidis</surname><given-names>G</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Shiosaka</surname><given-names>M</given-names></name><name><surname>Kawahata</surname><given-names>R</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Otsu</surname><given-names>M</given-names></name><name><surname>Obara</surname><given-names>N</given-names></name><name><surname>Sakata-Yanagimoto</surname><given-names>M</given-names></name><name><surname>Ishiyama</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Nolte</surname><given-names>F</given-names></name><name><surname>Hofmann</surname><given-names>W-K</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Sugano</surname><given-names>S</given-names></name><name><surname>Haferlach</surname><given-names>C</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Shih</surname><given-names>L-Y</given-names></name><name><surname>Haferlach</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Frequent pathway mutations of splicing machinery in myelodysplasia</article-title><source>Nature</source><volume>478</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nature10496</pub-id><pub-id pub-id-type="pmid">21909114</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>AM</given-names></name><name><surname>Lieu</surname><given-names>YK</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Manley</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1</article-title><source>Molecular Cell</source><volume>76</volume><fpage>82</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.07.017</pub-id><pub-id pub-id-type="pmid">31474574</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Will</surname><given-names>CL</given-names></name><name><surname>Bertram</surname><given-names>K</given-names></name><name><surname>Dybkov</surname><given-names>O</given-names></name><name><surname>Hartmuth</surname><given-names>K</given-names></name><name><surname>Agafonov</surname><given-names>DE</given-names></name><name><surname>Hofele</surname><given-names>R</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Kastner</surname><given-names>B</given-names></name><name><surname>Lührmann</surname><given-names>R</given-names></name><name><surname>Stark</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular architecture of the human 17S U2 snRNP</article-title><source>Nature</source><volume>583</volume><fpage>310</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2344-3</pub-id><pub-id pub-id-type="pmid">32494006</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y-J</given-names></name><name><surname>Wu</surname><given-names>L-Y</given-names></name><name><surname>Pang</surname><given-names>J-S</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma</article-title><source>Bioengineered</source><volume>12</volume><fpage>3978</fpage><lpage>3992</lpage><pub-id pub-id-type="doi">10.1080/21655979.2021.1948949</pub-id><pub-id pub-id-type="pmid">34288818</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80683.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.06.16.496393" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.16.496393"/></front-stub><body><p>This important study investigates the oncogenic and disease promoting potential of the K700E mutation in the splicing factor SF3B1 in a mouse model for pancreatic ductal adenocarcinoma (PDAC), finding that this mutation can promote disease progression both in the presence or absence of Trp53. They further identify SF3B1K700E-induced missplicing of Map3k7 as a critical mechanism that enables isolated pancreas cancer cells to survive TGFβ-induced EMT, senescence and cell death. Together with experiments based on convincing methods that suggest a conserved function in human PDAC, and indicating a specific role for the SF3B1 K700E mutation in early stage tumors, this study makes a valuable contribution to understanding of mechanisms regulating PDAC transformation, and will be interesting to researchers investigating pancreatic cancer.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80683.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.16.496393">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.06.16.496393v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Mutant SF3B1 promotes PDAC malignancy through TGF-β resistance&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Erica Golemis as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Additional experimentation testing the validity of findings in vivo is required. All three reviewers requested that data beyond organoids and cell lines be added. For example, orthotopic implantation of the organoids or cells used to examine how the Sf3B1-K700E mutant or Map3k7 expression affects tumor growth and metastasis in vivo is highly recommended as suggested by the reviewers.</p><p>2) Increase the human relevance through use of human PDAC lines that have the K700E mutation.</p><p>3) Articulate more clearly how the work is novel and distinguishes itself from previous work highlighting Map3k7 as downstream of the Sf3b1-K700E mutation in other cancers.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Additional analysis of the invasion properties following both expression of Sf3B1-K700E and also following Map3k7 expression, enhanced analysis of the PanINs and PDACs formed in KC and KPC +/- the Sf3b1-K700E mutation, examining effects of Map3k7 on tumors in vivo expressing Sf3b1-K700E would all add to the work significantly.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Increasing the human relevance of the study would greatly broaden the impact. Some suggestions are listed above. Another possibility would be to seek out cell lines with the SF3BP1 mutation if they are available.</p><p>Comment on figures and writing:</p><p>A scheme depicting the genotype of the mouse models, specifically of the SF3B1K700E allele would help the reader quickly determine whether the model is a knock-in, a transgenic mouse and so on.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>– The authors propose that SF3B1K700E functions much like SMAD4 mutations in blocking TGFb signaling. But the authors nevertheless propose that SF3B1K700E mutant tumors would nevertheless still benefit from further SMAD4 mutation, even though normally mutations that target the same pathway tend to be mutually exclusive, as SMAD4 may be a more potent block to TGFb signaling. From analysis of patient genomic data, can the authors determine if SF3B1K700E and SMAD4 mutations co-occur or if they are mutually exclusive? If they are mutually exclusive, would this not provide additional compelling patient in vivo evidence that the critical function of SF3B1K700E mutation is to tune TGFb signaling as SMAD4 mutations are no longer occurring in these samples?</p><p>– The authors show in figure 2F that KPC-SF3B1K700E cancer cells have a lower expression of EMT genes relative to KPC cell lines and further show in figure 3A that treatment with TGFβ is able to induce upregulation of some of these genes in KPC cells relative to control. As the main premise of the paper in the following figures becomes how the SF3B1K700E mutation can suppress and EMT lethal cell state promoted by TGFβ, it would be useful to see whether TGFβ treatment fails to induce upregulation of these genes in KPC-SF3B1K700E cancer cells relative to untreated control.</p><p>– While the authors show that lower expression of MAP3K7 can impair TGFB mediated cell death, a more nuanced discussion of the role MAP3K7 in programmed cell death is warranted, as there is ample literature on this subject, including how MAP3K7 inhibitor Takinib has been used in clinical trials against PDAC (PMID: 31695153, 25146924, 21743023).</p><p>– In figure 3B the authors show functional data that suggests SF3B1K700E pancreatic cancer cells have altered cell migration in a TGFβ-dependent context, likely related to the downregulation of EMT related genes observed before. If at all possible, whether these cells also exhibit an altered ability to metastasize in vivo (maybe by gross analysis of metastatic nodules or IHC of micro metastasis in other tissues) should also be commented on when describing the pathology of the mouse model.</p><p>– Figure 4 title should be modified to reflect the second main premise of the figure (4D-F), regarding regulation of MAP3K7.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80683.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Additional experimentation testing the validity of findings in vivo is required. All three reviewers requested that data beyond organoids and cell lines be added. For example, orthotopic implantation of the organoids or cells used to examine how the Sf3B1-K700E mutant or Map3k7 expression affects tumor growth and metastasis in vivo is highly recommended as suggested by the reviewers.</p></disp-quote><p>We thank the reviewers for raising this important point. To address their concerns, we established and analyzed three in vivo models:</p><list list-type="bullet"><list-item><p>Orthotopic transplantation of tumor-derived KPC and KPC-Sf3b1<sup>K700E</sup> cells (model of late-stage PDAC tumors)</p></list-item><list-item><p>Orthotopic transplantation of KPC cells with shRNA-mediated knockdown of Map3k7</p></list-item><list-item><p>Orthotopic transplantation of KPC-Sf3b1<sup>K700E</sup> cells overexpressing Map3k7</p></list-item></list><p>To briefly summarize our results, tumors derived from orthotopically transplanted KPC and KPC-Sf3b1<sup>K700E</sup> cells did not differ in size (see Figure 1—figure supplement 1M, N, and more detailed explanations in the response to Reviewer #1). Since orthotopic transplantation of KPC cells is a model of late-stage tumors (KPC cells are derived from fully developed PDAC tumors), these results are not surprising and support our initial hypothesis that Sf3b1<sup>K700E</sup> is more relevant in early stage PDAC rather than late stage PDAC. As expected from these results, also modulating the levels of Map3k7 did not have an effect in tumor growth in orthotopically transplanted KPC or KPC-Sf3b1<sup>K700E</sup> tumors (Author response image 1).</p><p>To further detangle the effect Sf3b1<sup>K700E</sup> at different tumor stages, we re-analyzed our autochthonous model at an early and late stage during tumor progression. Histological examination at 5 weeks revealed a significant increase in ADM and PanIN incidence (shown by MUC5AC and CK19 IF staining) and a concomitant decrease of acinar cells (shown by b-amylase staining) in KPC-Sf3b1<sup>K700E</sup> tumors (Figure 1G-J, see Figure 1—figure supplement 1J, K). Analyzing tumors at 9 weeks of age did not show differences in CK19 staining and fibrosis between KPC and KPC-Sf3b1<sup>K700E</sup> tumors anymore (see Figure 1—figure supplement 1F-I). These findings are in line with our autochthonous KRAS-G12D pre-cancer mouse model, in which Sf3b1<sup>K700E</sup> leads to a higher incidence of spontaneous progression of PanINs into PDAC (Figure 1L of the revised manuscript).</p><p>Taken together, orthotopic transplantation of KPC cells represents a late stage PDAC model, in which Sf3b1<sup>K700E</sup> does not have an influence on tumor growth anymore. Of note, in a previous study we tried to transplant in vitro induced pancreatic KPC organoids, but failed to observe any tumor growth in vivo. Thus, while using KPC cells isolated from fully established PDAC seems to be a requirement for the orthotopic transplantation, these cells, unfortunately, cannot be used to test whether Sf3b1<sup>K700E</sup> drives pancreatic tumor progression via MAP3K7. An autochtonous KPC model with downregulated Map3k7 or KPC-Sf3b1<sup>K700E</sup> model with overexpression of Map3k7 would need to be generated to test this hypothesis in vivo. However, it would take approximately 2 years to generate and breed such models, which would be out of scope for a revision. Therefore, in the revised manuscript we discuss the limitation of our study. In short, we explain that we could only show in vitro in cell lines and organoids that Sf3b1<sup>K700E</sup> leads to TGF-β resistance in pancreatic duct cells via missplicing of Map3k7, and that it would require further studies to proof that Map3k7 regulation is also relevant for PDAC progression in vivo (line 276-286).</p><disp-quote content-type="editor-comment"><p>2) Increase the human relevance through use of human PDAC lines that have the K700E mutation.</p></disp-quote><p>In the revised manuscript, we present multiple evidence showing the influence of SF3B1<sup>K700E</sup> on human PDAC lines. To summarize, we found that SF3B1<sup>K700E</sup> expression leads to Map3k7 missplicing in five human PDAC cell lines and one human pancreatic duct cell line (Figure 4F, see Figure 4—figure supplement 1D). Furthermore, human pancreatic duct cells that overexpress SF3B1<sup>K700E</sup> demonstrated a higher susceptibility to TGF-β-induced growth restriction compared to cells overexpressing wildtype SF3B1 (Figure 3J). We also executed wound healing assays to empirically evaluate the effect of SF3B1<sup>K700E</sup> on EMT in human PDAC cells. Consistent with our hypothesis, the results suggest that SF3B1<sup>K700E</sup> negatively impacts the migratory abilities of PANC-1 cells when treated with TGF-β. We have included these findings in the manuscript (Figure 2I, J). Lastly, we demonstrate that preconditioning human PANC-1 PDAC cells with a Map3k7 inhibitor before exposure to TGF-β1 significantly reduces their migratory capabilities in wound healing assays (Figure 5L, M).</p><disp-quote content-type="editor-comment"><p>3) Articulate more clearly how the work is novel and distinguishes itself from previous work highlighting Map3k7 as downstream of the Sf3b1-K700E mutation in other cancers.</p></disp-quote><p>In the revised manuscript we more clearly state that we are the first to demonstrate that (a) SF3B1<sup>K700E</sup> increases malignancy and reduces survival in a mouse model of PDAC (line 242-243) and (b) SF3B1<sup>K700E</sup> decreases sensitivity of murine and human pancreatic duct cells to the tumor suppressive effects of TGF-β (line 246-248). Of note, previous work describing that SF3B1<sup>K700E</sup> induces missplicing of Map3k7 did not provide a link to TGF-β-resistance and reduced survival. In addition, no other manuscript discussing SF3B1<sup>K700E</sup> induced missplicing of Map3k7 described the impact of reduced Map3k7 on EMT and apoptosis.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Additional analysis of the invasion properties following both expression of Sf3B1-K700E and also following Map3k7 expression, enhanced analysis of the PanINs and PDACs formed in KC and KPC +/- the Sf3b1-K700E mutation, examining effects of Map3k7 on tumors in vivo expressing Sf3b1-K700E would all add to the work significantly.</p></disp-quote><p>For analyzing the invasion properties, we performed wound healing assays / scratch assays with PANC-1 cells with inducible SF3B1 WT / K700E overexpression. We observed a significant difference in migratory capacity between SF3B1 WT / K700E overexpressing PANC-1 cells when stimulated with TGF-β. We added this data to the revised manuscript (Figure 2I, J). In addition, chemical inhibition of MAP3K7 with Takinib led to a reduced migration capacity in wound healing assays when PANC-1 cells were stimulated with TGF-β (Figure 5L, M).</p><p>To enhance the analysis of PanINs and PDAC in early- and late stage KPC and KPC-Sf3b1<sup>K700E</sup> tumors we assessed expression of CK19, MUC5A1 and b-Amylase by immunofluorescent histochemistry, as well as ADM structures. Significant differences were observed in early-stage tumors but not in late-stage tumors (Figure 1G-J, see Figure 1—figure supplement 1F-K).</p><p>To examine the effect of Map3k7 on tumors in vivo, we established orthotopic transplantation models with KPC and KPC-Sf3b1<sup>K700E</sup> cells, with overexpression and knockdown of Map3k7 (see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). However, in contrast to the autochthonous mouse model, orthotopically transplanted KPC and KPC-Sf3b1<sup>K700E</sup> cells did not show differences in tumor size (see Figure 1—figure supplement 1I, J). These data are not surprising, as orthotopic KPC transplantation is a late-stage cancer model (KPC cells are isolated from fully establish PDAC tumors), and our data suggest that Sf3b1<sup>K700E</sup> rather plays a role during early stages of PDAC development.</p><p>Importantly, our results that Sf3b1<sup>K700E</sup> does not affect growth of orthotopically transplanted KPC cells means that manipulating Map3k7 levels in this experimental setup should also not affect PDAC growth. Indeed, downregulation of Map3k7 via shRNA in KPC cells yielded tumors of comparable in size to tumors derived from control KPC cells (<xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>, B). Moreover, the EMT genes that were differentially expressed in our autochthonous (+/- K700E) mouse models were expressed at similar levels in shMap3k7 KPC tumors vs. control KPC tumors (<xref ref-type="fig" rid="sa2fig1">Author response image 1C</xref>). Likewise, overexpressing Map3k7 (OE Map3k7) in transplanted KPC-Sf3b1<sup>K700E</sup> cells led to the development of tumors of comparable size to control tumors without Map3k7 overexpression, again without differential expression of EMT genes between KPC-Sf3b1<sup>K700E</sup> cells with- and without Map3k7 overexpression (<xref ref-type="fig" rid="sa2fig1">Author response image 1D-F</xref>).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Impact of altered Map3k7 levels in an orthotopic PDAC model.</title><p>(<bold>A</bold>) Relative gene expression of Map3k7 in KPC cells transduced with shRNA targeting Map3k7 (shMap3k7), normalized to KPC cells transduced with scrambled control shRNA (shCtrl). 3 biological replicates are shown., error bar represents SD. (<bold>B</bold>) Weight of tumors derived by orthotopical transplantation of shMap3k7 and shCtrl KPC cells. 5 biological replicates are shown, error bar represents SEM. (<bold>C</bold>) Relative gene expression of EMT genes in tumors derived by orthotopic transplantation of shCtrl and shMap3k7 cells. 4 biological replicates are shown. (<bold>D</bold>) Relative gene expression of Map3k7 in KPC-Sf3b1<sup>K700E</sup> cells transduced with an overexpression vector of Map3k7 (OE Map3k7), normalized to control KPC cells without Map3k7 overexpression. 3 biological replicates are shown, error bar represents SD. A two-sided student’s t-test was used to calculate significance. (<bold>E</bold>) Weight of tumors derived by orthotopical transplantation of Map3k7 overexpressing KPC-Sf3b1<sup>K700E</sup> cells (n=5) and control KPC-Sf3b1<sup>K700E</sup> cells (n=4). Error bar represents SEM. (<bold>F</bold>) Relative gene expression of EMT genes in tumors derived by orthotopic transplantation of KPC-Sf3b1<sup>K700E</sup> cells with- and without overexpression of Map3k7. 4 biological replicates are shown. A two-sided student’s t-test was used to calculate significance in Figure 2A-F.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80683-sa2-fig1-v3.tif"/></fig><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Increasing the human relevance of the study would greatly broaden the impact. Some suggestions are listed above. Another possibility would be to seek out cell lines with the SF3BP1 mutation if they are available.</p></disp-quote><p>In the revised manuscript we present data on missplicing of MAP3K7 in 5 human PDAC cell lines and one human pancreatic duct cell line stably overexpressing SF3B1-K700E (Figure 4F). We further demonstrate that the human pancreatic duct cell line overexpressing SF3B1-K700E is less sensitive to growth inhibition by TGF-β than SF3B1-WT overexpressing cells, while the PDAC cell lines are insensitive to TGF-β, regardless of their genotype (Figure 3J, see Figure 3—figure supplement I). These data support our hypothesis that SF3B1-K700E decreases sensitivity to TGF-β induced apoptosis/growth inhibition in pancreatic duct cells, but that in late stage PDAC misregulation of other TGF-β modulating factors plays a more important role.</p><p>Furthermore, performing wound healing assays / scratch assays with human PANC-1 cells with inducible SF3B1-WT/ K700E overexpression revealed a significant difference in migratory capacity when stimulated with TGF-β. We added this data to the revised manuscript (Figure 2I, J).</p><disp-quote content-type="editor-comment"><p>Comment on figures and writing:</p><p>A scheme depicting the genotype of the mouse models, specifically of the SF3B1K700E allele would help the reader quickly determine whether the model is a knock-in, a transgenic mouse and so on.</p></disp-quote><p>We added a schematic overview of the SF3B1<sup>K700E</sup> knock-in to the revised manuscript (Figure 1A).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>– The authors propose that SF3B1K700E functions much like SMAD4 mutations in blocking TGFb signaling. But the authors nevertheless propose that SF3B1K700E mutant tumors would nevertheless still benefit from further SMAD4 mutation, even though normally mutations that target the same pathway tend to be mutually exclusive, as SMAD4 may be a more potent block to TGFb signaling. From analysis of patient genomic data, can the authors determine if SF3B1K700E and SMAD4 mutations co-occur or if they are mutually exclusive? If they are mutually exclusive, would this not provide additional compelling patient in vivo evidence that the critical function of SF3B1K700E mutation is to tune TGFb signaling as SMAD4 mutations are no longer occurring in these samples?</p></disp-quote><p>We performed a mutual exclusivity analysis with SF3B1-K700E and components of the TGF-β pathway in published human PDAC databases (www.cbioportal.org), but did not observe mutual exclusivity between these genes. Of note, the SF3B1-K700E mutation is rare, and due to the limited sample size (only 7 samples contain the SF3B1-K700E mutation) the value of the analysis is limited.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>Mutual exclusivity analysis of public PDAC databases (ICGC, CPTAC, QCMG, TCGA, UTSW), including 910 patients.</title><p>Mutation frequency is 25% for SMAD4, 5% for TGF-ΒR2, 3% for SMAD2, 2.6% for TGF-ΒR1, 1.4% for SMAD3, 0.7% for SF3B1-K700E, 0.7% for TGF-ΒR3, 0.4% for SMAD1. Analysis was performed on cbioportal.org.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>A</th><th>B</th><th>p-Value</th><th>q-Value</th><th>Tendency</th></tr></thead><tbody><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">SMAD1</td><td align="left" valign="top">0.974</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">SMAD2</td><td align="left" valign="top">0.823</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">SMAD3</td><td align="left" valign="top">0.917</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">SMAD4</td><td align="left" valign="top">0.524</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">TGF-ΒR1</td><td align="left" valign="top">0.851</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">TGF-ΒR2</td><td align="left" valign="top">0.268</td><td align="left" valign="top">0.682</td><td align="left" valign="top">Co-occurrence</td></tr><tr><td align="left" valign="top">SF3B1: MUT=K700E</td><td align="left" valign="top">TGF-ΒR3</td><td align="left" valign="top">0.961</td><td align="left" valign="top">0.974</td><td align="left" valign="top">Mutual exclusivity</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>– The authors show in figure 2F that KPC-SF3B1K700E cancer cells have a lower expression of EMT genes relative to KPC cell lines and further show in figure 3A that treatment with TGFβ is able to induce upregulation of some of these genes in KPC cells relative to control. As the main premise of the paper in the following figures becomes how the SF3B1K700E mutation can suppress and EMT lethal cell state promoted by TGFβ, it would be useful to see whether TGFβ treatment fails to induce upregulation of these genes in KPC-SF3B1K700E cancer cells relative to untreated control.</p></disp-quote><p>For the revised manuscript, we assessed the expression of the EMT-gene set of KPC and KPC-SF3B1<sup>K700E</sup> cells stimulated with TGF-β. Indeed, 6 of 9 genes showed no or impaired upregulation in KPC-SF3B1<sup>K700E</sup> cells in comparison to KPC-SF3B1 (see Figure 2—figure supplement 1G)</p><disp-quote content-type="editor-comment"><p>– While the authors show that lower expression of MAP3K7 can impair TGFB mediated cell death, a more nuanced discussion of the role MAP3K7 in programmed cell death is warranted, as there is ample literature on this subject, including how MAP3K7 inhibitor Takinib has been used in clinical trials against PDAC (PMID: 31695153, 25146924, 21743023).</p></disp-quote><p>In the revised manuscript, we discuss the multi-faceted role of MAP3K7 in apoptosis (line 269-275).</p><disp-quote content-type="editor-comment"><p>– In figure 3B the authors show functional data that suggests SF3B1K700E pancreatic cancer cells have altered cell migration in a TGFβ-dependent context, likely related to the downregulation of EMT related genes observed before. If at all possible, whether these cells also exhibit an altered ability to metastasize in vivo (maybe by gross analysis of metastatic nodules or IHC of micrometastasis in other tissues) should also be commented on when describing the pathology of the mouse model.</p></disp-quote><p>We analyzed macroscopic metastatic nodules in the liver of KPC and KPC-SF3B1<sup>K700E</sup> mice. We found that 2 out of 32 KPC mice vs. 5 of 22 KPC-SF3B1<sup>K700E</sup> mice developed macro-metastases in liver (of animals older than 56 days). However, this difference is statistically not significant (chi-square test, p=0.37), and the role of EMT in metastasis formation is complex and controversial. We therefore did not add this data to the manuscript.</p><disp-quote content-type="editor-comment"><p>– Figure 4 title should be modified to reflect the second main premise of the figure (4D-F), regarding regulation of MAP3K7.</p></disp-quote><p>We changed the title of Figure 4 accordingly (line 806).</p></body></sub-article></article>